

509,894
Rec'd PCT/PTO 01 OCT 2004

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087062 A2

(51) International Patent Classification⁷: C07D 231/12,
401/04, 307/46, 263/38, 277/34, 261/08, A61K 31/34,
31/415, 31/42, 31/425, 31/44, A61P 29/00

[IN/IN]; Zydus Towers, Satellite Cross Roads, Ahmedabad
380 015, Gujarat, India (IN).

(21) International Application Number: PCT/IN03/00133

(74) Agents: SUBRAMANIAM, Hariharan et al.; Subrama-
niam, Nataraj and Associates, E-556 Greater Kailash II,
New Delhi 110 048, Maharashtra (IN).

(22) International Filing Date: 1 April 2003 (01.04.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
327/MUM/2002 5 April 2002 (05.04.2002) IN

(71) Applicant (*for all designated States except US*): CADILA
HEALTHCARE LIMITED [IN/IN]; Zydus Tower, Satel-
lite Cross Roads, Ahmedabad 380 015, Gujarat (IN).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): LOHRAY, Braj,
Bhushan [IN/IN]; Zydus Tower, Satellite Cross Roads,
Ahmedabad 380 015, Gujarat (IN). LOHRAY, Vidya,
Bhushan [IN/IN]; Zydus Tower, Satellite Cross Roads,
Ahmedabad 380 015, Gujarat (IN). JAIN, Mukul, R.
[IN/IN]; Zydus Towers, Satellite Cross Roads, Ahmed-
abad 380 015, Gujarat, India (IN). PATEL, Gautam, D.
[IN/IN]; Zydus Towers, Satellite Cross Roads, Ahmedabad
380 015, Gujarat, India (IN). PINGALI, Harikishore

Published:

— without international search report and to be republished
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: NEW HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COM-
POSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE

(57) Abstract: The present invention describes novel compounds having antiinflammatory activity, process for their preparation and
pharmaceutical composition containing them.


BEST AVAILABLE COPY

WO 03/087062 A2

NEW HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE

5 Field of Invention

The present invention relates to novel compounds of general formula (I), their analogs, their derivatives, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, where G represents substituted or unsubstituted, single or fused groups selected from aryl group, heteroaryl or heterocyclic groups. Preferably, G represents the groups A, B, C, D, E & F as described below. The present invention also relates to a process of preparing compounds of general formula (I), their analogs, derivatives, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.



The compounds of the present invention are useful in the treatment of inflammatory diseases, preferably, wherein prostaglandins play a pathophysiological role. Their role have been implicated in a number of diseases which includes rheumatoid arthritis and osteoarthritis, pyrexia, asthma, bone resorption, cardiovascular diseases, dysmenorrhea, premature labour, nephritis, nephrosis, atherosclerosis, hypotension, shock, pain, cancer, and alzheimer disease.

Background to the invention

Inflammation is a disorder, which is characterized by redness, fever, swelling and pain. Prostaglandins play a major role in the inflammation process and inhibition of prostaglandin production, especially of PGG_2 , PGH_2 and PGE_2 has been a common target

to treat inflammation. However, NSAIDs that are commonly used to treat prostaglandin-induced pain and inflammation also effect other prostaglandin-regulated processes not associated with inflammation process. This leads to severe side effects including life threatening gastric ulcers dyspepsia & nephrotoxicity, thereby reducing their therapeutic use.

Previously, NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX). In early 1990s, COX was demonstrated to exist as two distinct isoforms COX-1 and COX-2 (*PNAS* (1991) 88, 2692-96) and recently a third isoform COX-3 has been discovered from brain (*PNAS* (2002) 99, 13926-13931). COX-1 & COX-2 serve different physiological and pathophysiological functions. COX-1 is the constitutive isoform & is mainly responsible for the synthesis of cytoprotective prostaglandins in the GI tract and for the synthesis of thromboxane, which triggers platelet aggregation in blood platelets. COX-2 is believed to be an inducible isoform, which is stimulated in response to endotoxins, cytokines, and mitogens. Importantly, COX-2 plays a major role in prostaglandin biosynthesis in inflammatory cells (monocytes/macrophages) and in the central nervous system. (*Current Medicinal Chemistry* (2000) 7, 1041-62). The use of COX-2 as anti-cancer agents is discussed in *Curr Drug Targets* 2001 Mar;2 (1):79-106. Hence, the difference in the function of COX-1 & COX-2 provides a goal of separating the toxicity, particularly related to the gastrointestinal tract from efficacy of NSAIDs by developing drugs that are selective COX-2 inhibitors as anti-inflammatory, analgesic, and/or antipyretic agents. It is believed that these compounds would have minimum or no GI & hematologic liabilities from COX-1 inhibition that plague almost all currently marketed NSAIDs, most of which inhibit both COX-1 & COX-2, with specificity for COX-1 inhibition greatly exceeding that for COX-2 inhibition. Celecoxib and Rofecoxib were the first two selective COX-2 inhibitors approved for selected markets for the treatment of certain inflammatory conditions.

Although, the concept of selectively inhibiting COX-2 in order to have better efficacy & safety looks quite very attractive, recent clinical studies have raised doubts about the long term efficacy of selective COX-2 inhibitors. Celecoxib was not found to be any better than other NSAIDs in long-term clinical study (*BMJ* (2002) 324, 1287-88). On the other hand highly selective COX-2 inhibitors produce adverse cardiovascular

effects that are not seen in non-selective COX inhibitors (*Science* (2002) 296, 539-541; *JAMA* (2001) 268 954-959).

The references below disclose anti-inflammatory compounds that are selective COX-2 inhibitors. Increasing number of publications & patents emerging steadily indicates continuing efforts to find a safe and effective anti-inflammatory agent. Such novel compounds, their methods for preparation are described in EP1006114, EP1099695, EP418845, EP554829, EP0863134, EP0714895, EP0799523, GB2294879, US5474995, US5486534, US5510368, US5686460, US5691374, US5710140, US5723485, US5776967, US5981576, US5922742, US6083969, US6071954, US6071936, US6133292, US6143892, US6274590, WO9415932, WO9427980, WO9500501, WO9515315, WO9515316, WO9515317, WO9515318, WO9518799, WO9603387, WO9603392, WO9606840, WO9609304, WO9610012, WO9616934, WO9619469, WO9621667, WO9623786, WO9624585, WO9625405, WO9631509, WO9636623, WO9637467, WO9638418, WO9636617, WO9703667, WO9703953, WO9713755, WO9714691, WO9716435, WO9727181, WO9734882, WO9737984, WO9746524, WO97727181, WO9804527, WO9807425, WO9807714, WO9811080, WO9813483, WO9816227, WO9821195, WO9822442, WO9825896, WO9841511, WO9841516, WO9843966, WO9852940, WO9910331, WO9910332, WO9912930, WO9915503, WO9923087, WO9935130, WO0026216, WO0052008, WO0024719, WO0134577, WO0140216.


In addition to COX, the enzyme lipooxygenase (LOX) also plays an important role in inflammation, 5-LOX products such as LTB₄, LTC₄ and LTD₄ are involved in a variety of pathological processes (*Pharmacol Rev* (2003), 55 195-227). Therefore, inhibition of 5-LOX activity may produce beneficial effects in inflammation. Studies have indicated that dual inhibitors of COX and LOX may have better safety profile (*Pharmacol Res* (2001), 43 429-436) than non-selective NSAIDs. The compounds of the present invention are useful in treating inflammatory conditions caused by increased activities of COX and/or LOX enzymes.

Cytokines are known to be involved in inflammatory processes. Tumor necrosis factor α (TNF- α) is described as a key proinflammatory mediator in autoimmune diseases. This 26 kDa enzyme is membrane associated until processed into a smaller (17 kDa) soluble form by TNF- α converting enzyme (TACE). The compounds of the present invention

are also useful in the treatment of inflammatory diseases such as arthritis by inhibiting TNF- α , or TACE or by inhibiting the production of Tumor necrosis factor- α .

Summary of the invention

The present invention describes a group of novel compounds useful in the treatment of inflammatory diseases, cytokine related, specially, TNF- α mediated diseases, cyclooxygenase related diseases, like inflammation and pain. The novel compounds are defined by the general formula (I) wherein G represents substituted or unsubstituted, single or fused groups selected from aryl group, heteroaryl or heterocyclic groups containing one or more heteroatom selected from O, S, N, preferably, G represents the groups A, B, C, D, E & F as described below:



The compounds of the present invention are useful in the treatment of the human or animal body, in particular for the treatment of pain, fever or inflammation, to inhibit prostanoind-induced smooth muscle contraction or for the prevention of colorectal cancer. They are also useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever and neuropathic pain, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhoea, headache, toothache, sprains and strains, myostis, neuralgia, synovitis, bursitis, tendinitis, injuries following surgical and dental procedures, post-operative inflammation including ophthalmic surgery such as cataract and refractive surgery, menstrual cramps, premature labor, These compounds may also be used in the treatment of arthritis, such as rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, skin inflammation

disorders such as psoriasis, eczema, burning and dermatitis with better efficacy, potency and minimum toxic effects.

The main objective of the present invention thus is to provide novel compounds of general formula (I), their analogs, derivatives, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures.


Another objective of the present invention is to provide a process for the preparation of novel compounds of general formula (I), their analogs, derivatives, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

The present invention also aims at providing pharmaceutical compositions containing compounds of general formula (I), their analogs, derivatives, their tautomeric forms, their pharmaceutically acceptable salts, solvates, and their mixtures having pharmaceutically acceptable carriers, solvents, diluents and other media normally employed in their manufacture.

The compounds of the present invention provides a method of treatment of cyclooxygenase mediated diseases, by administering a therapeutically effective & non-toxic amount of the compound of formula (I) or their pharmaceutically acceptable compositions to the mammals.


Detailed Description of the Invention

The novel compounds of the present invention are defined by the general formula (I) wherein G represents substituted or unsubstituted, single or fused groups selected from aryl group, heteroaryl or heterocyclic groups containing one or more heteroatom selected from O, S, N, preferably, G represents the groups A, B, C, D, E & F as described below:




(I)


G =




D




B




C



D



E



F

where R₁ represents hydrogen, substituted or unsubstituted groups selected from alkyl, aralkyl, acyl, alkylsulfonyl, arylsulfonyl groups; R₂ represents alkyl, aralkyl, alkoxy or -NHR where R represents hydrogen or lower alkyl groups which may be suitably substituted;

X₁, X₂, X₃, X₄ may be same or different and represent

hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino, thio, hydroxy, or substituted or unsubstituted groups selected from alkyl which may be linear or branched, alkenyl, cycloalkyl, alkoxy, cycloalkoxy, cycloalkoxyalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, carboxyalkyl, haloalkyl, aminoalkyl, cyanoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkyl, acyl, acyloxy, acyloxyalkyl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aralkenyl, acylamino, alkylamino, dialkylamino, aralkylamino, alkoxyamino, hydroxylamino, alkoxycarbonyl, aralkoxycarbonyl groups; two adjacent groups may form a methylenedioxy or a ethylenedioxy group; when G represents heterocycle "D", then atleast one of the groups defined by X₁, X₂, X₃, X₄ is not hydrogen;

- R₃ is selected from substituted or unsubstituted alkyl, substituted or unsubstituted, single or fused groups selected from aryl, aralkenyl, heteroaryl or heterocyclic groups; R₄ and R₅ is selected from hydrogen atom, halogen atom, carboxy, substituted or unsubstituted groups selected from linear or branched alkyl, haloalkyl polyhaloalkyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, phenyl groups; Y represents O or S; W represents O or S;
- Suitable substituents on R₃ and R₄ may be selected from cyano, nitro, halo, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy, ONO₂, alkyl-ONO₂ or substituted or unsubstituted groups selected from alkyl which may be linear or branched, perhaloalkyl, alkoxy, hydrazinoalkyl, alkylhydrazido, acyl, acyloxy, oxo, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfoximinyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aryloxycarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkoxycarbonylalkyl,

amidino, carboxamidoalkyl, acylamino, cyanoamidino, cyanoalkyl, N-aminocarbonylalkyl, N-arylaminocarbonyl, carboxyalkylaminocarboxy, N-alkylamino, N,N-dialkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, arylthio, aralkylthio, N-alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N,N-dialkylaminosulfonyl, N-alkyl-N-arylaminosulfonyl, alkoxycarbonyl, aminocarbonyl, cycloalkyl, heterocyclic, heterocyclicalkyl, heteroaryl, heteroaralkyl, heteroaralkoxy, sulfamyl groups; two adjacent groups may form a methylenedioxy or a ethylenedioxy group;

Suitable substituents on X₁, X₂, X₃, X₄ may be selected from cyano, nitro, halo, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy or substituted or unsubstituted groups selected from alkyl which may be linear or branched, alkoxy, alkoxycarbonyl, acyl, acylamino, acyloxy, hydrazinoalkyl, alkylhydrazido, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, alkoxycarbonyl, amidino groups;

Where the term "alkyl" is used anywhere in the specification, either alone or within other terms such as "haloalkyl", "hydroxyalkyl", "alkylthio", "alkylsulfonyl" etc. it includes linear or branched radicals having one to ten carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to six carbon atoms. Examples of such radicals include but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, isohexyl, heptyl, octyl etc. The term "alkenyl" includes linear or branched radicals having at least one carbon-carbon double bond of two to ten carbon atoms or, preferably, two to six carbon atoms. Examples of such radicals include ethenyl, n-propenyl, butenyl, and the like. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine atoms. The term "haloalkyl" includes radicals wherein any one or more of the alkyl carbon atoms is substituted with halogen atoms as defined above. Examples include monohaloalkyl, dihaloalkyl, polyhaloalkyl and similar radicals. A monohaloalkyl radical, for example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. The alkyl group in haloalkyl group is a lower alkyl group and is termed lower

haloalkyl group. "Lower haloalkyl" includes radicals having 1-6 carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloroethyl, pentafluoroethyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, and the likes.

- 5 The term "hydroxyalkyl" includes linear or branched alkyl radicals having one to ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, and
- 10 hydroxyhexyl.

- The terms "alkoxy" and "alkoxyalkyl" includes linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms, such as methoxy radical. Preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-
- 15 butoxy. The term "alkoxyalkyl" also includes alkyl radicals having two or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. Preferred alkoxyalkyl radicals are "lower alkoxyalkyl" radicals having one to six carbon atoms and one or two alkoxy radicals. Examples of such radicals include methoxymethyl, methoxyethyl, ethoxyethyl, methoxybutyl, methoxypropyl and the like.
- 20 The "alkoxy" or "alkoxyalkyl" radicals may further contain substitution consisting of one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" or "haloalkoxyalkyl" radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and the like.

- The term "aryl", alone or in combination, includes carbocyclic aromatic system
- 25 containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused. The term "aryl" includes aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. The term "heterocyclic" includes saturated, partially saturated and unsaturated ring-shaped radicals, the heteroatoms selected from either nitrogen, sulfur and oxygen. Examples of saturated
- 30 heterocyclic radicals include saturated 3 to 7 membered heterocyclic group containing one or more heteroatoms selected from N, O and S. Examples of such groups include but are not limited to aziridinyl, azetidiny, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl,

morpholinyl, thiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxazepinyl, thiazepinyl, oxazolidinyl, thiazolidinyl and the like; examples of partially saturated heterocyclic radicals include dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole and the like; the term "heteroaryl" includes unsaturated heterocyclic radicals. Examples of unsaturated heterocyclic radicals, also termed "heteroaryl" radicals include unsaturated 5 to 6 membered heteromonocyclic, fused polycyclic heteroaryl or fused polycyclic heterocycle groups containing one or more heteroatoms selected from O, N, S. Example of such groups include but not limited to pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl, (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-tetrazolyl etc.), indolyl, isoindolyl, dihydroindolyl, benzofuryl, 2,3-dihydrobenzofuryl, chromanyl, benzopyran, thiochromanyl, benzothiopyran, benzodioxolyl, benzodioxanyl, pyridyl, thienyl, benzothienyl, oxazolyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl, pyranyl, 2-furyl, 3-furyl, pthalazinyl, quinazolinyl, quinolinyl, isoquinolinyl, benzoxazolyl, benzoxadiazolyl, thiazolyl, thiadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuran, benzothiophene, and the like. The aforesaid "heterocyclic or heteroaryl group" may have 1 to 4 substituents such as lower alkyl, haloalkyl, dihaloalkyl, trihaloalkyl, hydroxy, oxo, amino and lower alkylamino, lower alkoxy, halo, lower thioalkyl, acyl, acylamino groups. Preferred heterocyclic radicals include five to ten membered fused or unfused radicals and more preferable examples of heteroaryl radicals include benzofuryl, 2,3-dihydrobenzofuryl, benzothienyl, indolyl, dihydroindolyl, chromanyl, benzopyran, thiochromanyl, benzothiopyran, benzodioxolyl, benzodioxanyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, pyrazinyl, pthalazinyl, quinazolinyl, quinolinyl, isoquinolinyl, benzoxazolyl, benzothiazolyl, and the like.

The term "hydrazino" used herein, either alone or in combination with other radicals, denotes $-NHNH-$, suitably substituted with other radicals, such as alkyl hydrazino, where an alkyl group, as defined above is attached to a hydrazino group.

The term "sulfonyl", used alone or in combination with other terms such as alkylsulfonyl, denotes respectively divalent radicals $-SO_2-$. "Alkylsulfonyl" includes alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are lower alkylsulfonyl radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The term "arylsulfonyl" includes aryl radicals as

defined above, attached to a sulfonyl radical. Examples of such radicals include phenylsulfonyl. The terms "sulfamyl," "aminosulfonyl" and "sulfonamidyl," whether alone or used with terms such as "N-alkylaminosulfonyl" and "N-arylamino-sulfonyl," "N,N-dialkylaminosulfonyl," "N-alkyl-N-arylamino-sulfonyl", denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide ($-\text{SO}_2\text{NH}_2$). The terms "N-arylamino-sulfonyl" and "N,N-dialkylaminosulfonyl" denote sulfamyl radicals substituted, respectively with one alkyl radical, or two alkyl radicals. More preferred alkylaminosulfonyl radicals are "lower alkylaminosulfonyl" radicals having one to six carbon atoms. Examples of such lower alkylaminosulfonyl radicals include N-methylaminosulfonyl, N-ethylaminosulfonyl, N-methyl-N-ethylaminosulfonyl and the like. The terms "N-arylamino-sulfonyl" and "N-alkyl-N-arylamino-sulfonyl" denote sulfamyl radicals substituted respectively with one aryl radical or one alkyl and one aryl radical. Preferred N-alkyl-N-arylamino-sulfonyl radicals are lower N-alkyl-N-arylsulfonyl radicals having alkyl radicals of one to six carbon atoms. Examples of such lower N-alkyl-N-arylsulfonyl radicals are N-ethyl-phenylaminosulfonyl and the like.

The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes $-\text{CO}_2\text{H}$. The terms "alkanoyl" or "acyl" include radicals derived from carboxylic acids and include but not limited to substituted or unsubstituted groups selected from formyl, acetyl, propionyl (propanoyl), butanoyl (butyryl), isobutanoyl (isobutyryl), valeryl (pentanoyl), isovaleryl, pivaloyl, hexanoyl, benzoyl or the like. The term "carbonyl" used either alone or with other terms, such as "alkylcarbonyl", denotes $-(\text{C}=\text{O})-$. The term "alkylcarbonyl" includes radicals having a carbonyl radical substituted with an alkyl radical such as acyl or alkanoyl described above. The term "alkylcarbonylalkyl" denotes an alkyl radical substituted with an "alkylcarbonyl" radical. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. Preferably, "lower alkoxycarbonyl" includes alkoxy radicals having one to six carbon atoms. Examples of such "lower alkoxycarbonyl" ester radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The term "alkoxycarbonylalkyl" includes radicals having "alkoxycarbonyl", as defined above substituted to an alkyl radical. Preferred alkoxycarbonylalkyl radicals are "lower alkoxycarbonylalkyl" having lower alkoxycarbonyl radicals as defined above attached to one to six carbon atoms for

example methoxycarbonylmethyl, tert-butoxycarbonylethyl, and methoxycarbonylethyl. The term "aminocarbonyl" when used separately or with other terms such as "aminocarbonylalkyl", "N-alkylaminocarbonyl", "N-arylamino carbonyl", "N,N-dialkylaminocarbonyl", "N-alkyl-N-arylamino carbonyl", "N-alkyl-N-hydroxyaminocarbonyl" and "N-alkyl-N-hydroxyaminocarbonylalkyl", substituted or unsubstituted. The terms "N-alkylaminocarbonyl" and "N,N-dialkylaminocarbonyl" denote aminocarbonyl radicals which have been substituted with one alkyl radical and with two alkyl radicals, respectively. Preferred are "lower alkylaminocarbonyl" having lower alkyl radicals as described above attached to aminocarbonyl radical. The terms "N-arylamino carbonyl" and "N-alkyl-N-arylamino carbonyl" denote aminocarbonyl radicals substituted, respectively, with one aryl radical, or one alkyl and one aryl radical. The term "aminocarbonylalkyl" includes alkyl radicals substituted with aminocarbonyl radicals.

The term "amidino" denotes an $-C(=NH)-NH_2$ radical. The term "cyanoamidino" denotes an $-C(=N-CN)-NH_2$ radical. The term "heterocyclicalkyl" includes heterocyclic-substituted alkyl radicals. More preferred heterocyclicalkyl radicals are "lower heterocyclicalkyl" radicals having one to six carbon atoms and a heterocyclic radical. Examples include such radicals as pyrrolidinylmethyl, pyridylmethyl and thienylmethyl. The term "aralkyl" includes aryl-substituted alkyl radicals. Preferable aralkyl radicals are "lower aralkyl" radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms. Examples of such radicals include benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, diphenylethyl and the like. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxy, amino, acylamino, alkoxycarbonyl, alkylthio and the like. The terms benzyl and phenylmethyl are interchangeable. The term "cycloalkyl" includes radicals having three to ten carbon atoms. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to seven carbon atoms. Examples include radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. The term "cycloalkenyl" includes unsaturated cyclic radicals having three to ten carbon atoms, such as cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and the like. The term "alkylthio" includes radicals containing a linear or branched alkyl radical attached to a divalent sulfur atom. Example of alkylthio are methylthio (CH_3-S-), ethylthio, butylthio, and the like. The

term "alkylsulfinyl" includes radicals containing a linear or branched alkyl radical attached to a divalent-S(=O)-atom.

The term "aminoalkyl" includes alkyl radicals substituted with amino radicals. Preferred aminoalkyl radicals are "lower aminoalkyl" having one to six carbon atoms. Examples include aminomethyl, aminoethyl and aminobutyl. The term "alkylaminoalkyl" includes aminoalkyl radicals having the nitrogen atom substituted with at least one alkyl radical. Preferred alkylaminoalkyl radicals are "lower alkylaminoalkyl" having one to six carbon atoms attached to a lower aminoalkyl radical as described above. The terms "N-alkylamino" and "N,N-dialkylamino" denote amino groups which have been substituted with one alkyl radical and with two alkyl radicals, respectively. Preferred alkylamino radicals are "lower alkylamino" radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Suitable "alkylamino" may be N,N-dimethylamino, N,N-diethylamino or the like. The term "arylamino" denotes amino groups which have been substituted with one or two aryl radicals, such as N-phenylamino. The "arylamino" radicals may be further substituted on the aryl ring portion of the radical. The term "aralkylamino" denotes amino groups which have been substituted with one or two aralkyl radicals, such as N-benzylamino. The "aralkylamino" radicals may be further substituted on the aryl ring portion of the radical. The terms "N-alkyl-N-arylamino" and "N-aralkyl-N-alkylamino" denote amino groups which have been substituted with one aralkyl and one alkyl radical, or one aryl and one alkyl radical; respectively, to an amino group. The terms "N-arylaminoalkyl" and "N-aralkylaminoalkyl" denote amino groups which have been substituted with one aryl radical or one aralkyl radical, respectively, and having the amino group attached to an alkyl radical. Preferred arylaminoalkyl radicals are "lower arylaminoalkyl" having the arylamino radical attached to one to six carbon atoms. Examples of such radicals include N-phenylaminomethyl and N-phenyl-N-methylaminomethyl. The terms "N-alkyl-N-arylaminoalkyl" and "N-aralkyl-N-alkylaminoalkyl" denotes N-alkyl-N-arylamino and N-alkyl-N-aralkylamino groups, respectively, and having the amino group attached to alkyl radicals. The term "acyl", whether used alone, or with another term such as "acylamino" denotes a radical provided by the residue after removal of hydroxyl from an organic acid. The term "acylamino" includes an amino radical substituted with an acyl group. Examples of an "acylamino" radical is acetylamino or acetamido ($\text{CH}_3\text{C}(=\text{O})\text{-NH-}$) where the amine may be further substituted with alkyl, aryl, or aralkyl. The term

"arylthio" includes aryl radicals of six to ten carbon atoms, attached to a divalent sulfur atom. An example of "arylthio" is phenylthio. The term "aralkylthio" includes aralkyl radicals as described above, attached to a divalent sulfur atom. An example of "aralkylthio" is benzylthio. The term "aryloxy" includes aryl radicals, as defined above, attached to an oxygen atom. Examples of such radicals include phenoxy. The term "aralkoxy" includes oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. Preferred aralkoxy radicals are "lower aralkoxy" radicals having phenyl radicals attached to lower alkoxy radical as described above. The term "haloaralkyl" includes aryl radicals as defined above "carboxyhaloalkyl" includes carboxyalkyl radicals as defined above having halo radicals attached to the alkyl portion. The term "aralkenyl" includes aryl radicals attached to alkenyl radicals having two to ene carbon atoms, such as phenylbutenyl, and phenylethenyl or styryl.

Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.


Particularly useful compounds according to the present invention includes 5-(4-Fluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(4-Chlorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(4-Methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(4-Methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 1-(4-methylsulfoximinyphenyl)-5-(4-*n*-propoxyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(4-Ethoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(4-Hydroxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(3-Chloro-4-fluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(3,4-Difluorophenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(4-Fluoro-3-methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(4-Methoxy-3-methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(3-Chloro-4-methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(3-Bromo-4-methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(3-Fluoro-4-methoxyphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 5-(3-Methoxy-4-methylphenyl)-1-(4-methylsulfoximinyphenyl)-3-trifluoromethyl-1H-pyrazole
 1-(2-Fluoro-4-methylsulfoximinyphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 1-(3-

- Fluoro-4-methylsulfoximinylphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole 1-(4-Methylsulfoximinylphenyl)-5-phenyl-3-trifluoromethyl-1H-pyrazole 1-(4-Methylsulfoximinylphenyl)-5-(1-naphthyl)-3-trifluoromethyl-1H-pyrazole 5-(4-Methoxyphenyl)- 3-methyl-1-(4-methylsulfoximinylphenyl)-1H-pyrazole 1-(4-Methylsulfoximinylphenyl)-5-(4-nitrophenyl)-3-trifluoromethyl-1H-pyrazole 5-(3-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole 5-(3,5-Difluoro-4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole 5-(3-Hydroxy-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole 5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazole-3-carboxylicacid 3-(Hydroxymethyl)-5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazole 5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazol-3-ylmethylhydrogen sulphate 5-{4-(2-Hydroxyethoxy)phenyl}-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole 1-(4-Methylsulfoximinylphenyl)-5-(4-pyridyl)-3-trifluoromethyl-1H-pyrazole 1-(4-Methylsulfoximinylphenyl)-5-(3-pyridyl)-3-trifluoromethyl-1H-pyrazole 1-(4-Methylsulfoximinylphenyl)-5-(2-pyridyl)-3-trifluoromethyl-1H-pyrazole 5-(4-Isopropoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole 1-(4-Methylsulfoximinylphenyl)-5-(2-thiophenyl)- 3-trifluoromethyl-1H-pyrazole 5-(4-Methylsulfoximinylphenyl)-1-phenyl -3- trifluoromethyl- 1H- pyrazole. 1-(4-Methoxyphenyl)-5-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole 5-Ethyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole 5-Methoxymethyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole 3-(4-Fluorophenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole 3-(4-Chlorophenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole 3-Ethyl-4-(4-methylsulfoximinylphenyl)-5-phenyl-isoxazole 5-Chloro-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole 5-Methyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole 3-(4-Methoxyphenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole 3-(3,4-Dichlorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one 3-(4-Chlorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one 3-Phenyl-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one 3-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one 3-(3,4-Dimethoxyphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one 3-(4-Methoxyphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one 3-(4-Methylphenyl)-4-(3-fluoro-4-

methylsulfoximinylphenyl)-5H-furan-2-one 5-Chloro-3-(4-methylsulfoximinylphenyl)-
 6'-methyl-[2,3']bipyridinyl 5-Chloro-3-(4-methylsulfoximinylphenyl)-[2,3']bipyridinyl
 3-(3-Fluorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-thiazol-2-one 3-(3,4-
 Dichlorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one 3-(3,4-
 5 Dichlorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-thiazol-2-one 3-(2-Fluorophenyl)-
 4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one 3-(4-Bromophenyl)-4-(4-
 methylsulfoximinylphenyl)-3H-oxazol-2-one 4-(4-Methylsulfoximinylphenyl)-3-phenyl-
 3H-oxazol-2-one 3-(3,4-Dichlorophenyl)-4-[4-(N-chloroacetyl) methylsulfoximinyl-
 phenyl]-3H-oxazol-2-one 3-(3,4-Dichlorophenyl)-4-[4-(N-acetyl) methylsulfoximinyl-
 10 phenyl]-3H-oxazol-2-one 3-(3,4-Dichlorophenyl)-4-[4-(N-
 methylsulfonyl)methylsulfoximinyl-phenyl]-3H-oxazol-2-one 3-(3,4-Dichlorophenyl)-4-
 [4-{N-(4-methylphenyl)sulfonyl}-methylsulfoximinyl-phenyl]-3H-oxazol-2-one

The present invention also provides methods for the preparation of novel
 compounds described in the general formula (I), their tautomeric forms, their derivatives,
 15 their analogs, their pharmaceutically acceptable salts and their pharmaceutically
 acceptable solvates, wherein all symbols are as defined earlier. The process comprising:

Oxidizing a compound of formula (P) to get a compound of formula (Q) which is
 iminated with suitable reagents get compound of formula (I) which may further be
 converted to their pharmaceutically acceptable salts, if desired.



20

A detailed process with different G groups are outlined in the schemes:

Method B:

The mercapto compounds of formula P may be converted to the respective
 25 sulfoxides of formula Q by reacting with an oxidizing agent. Suitable oxidizing agents
 may be selected from but not limited to peroxides and peroxyacids and their salts.
 Suitable oxidizing agent is selected from H₂O₂, meta-peroxides of Na, K, and the like,
 oxone®, sodium perborate, sodium tungstate and the like, peracetic acid, m-
 chloroperbenzoic acid, magnesium monoperoxyphthalate, and the like. Suitable solvents


are based on the oxidizing agents used and are selected from water, acetic acid, acetonitrile, dichloromethane, acetone, THF, methanol, ethanol and the like or a mixture thereof. Reaction temperature may range from -78°C to 40°C , based on the solvent used.

5 **Method C:**

10 The sulfoxide compounds of formula Q may be converted to sulfoximine compounds of formula (I) by reacting with suitable iminating agents such as hydrazoic acid (HN_3) which may be generated by the reaction of NaN_3 with conc. sulfuric acid in solvents such as CH_2Cl_2 , CHCl_3 and the like. Temperature in the range -10°C to reflux temperature of the solvent(s) used may be used. Alternatively, sulfoxides of formula IV or V may be treated with O-substituted hydroxylamines, such as O-mesitylenesulfonylhydroxylamine (MSH), followed by a base such as KOH, NaOH, NaHCO_3 and the like. Solvents such as CH_2Cl_2 , CHCl_3 may be used.

15 **Scheme I**

The compounds of general formula (IA) wherein all the symbols are as defined earlier, may be prepared by one or more routes or combinations of reactions outlined in Scheme I below which comprises:



i) Reacting a compound of formula II wherein, R_2 , R_4 , X_1 , X_2 , X_3 , X_4 are as defined earlier and Hal represents a halogen atom such as chlorine, bromine or iodine atom with an aryl thiocarbamate III to yield a compound of formula V, after dehydration of the intermediate IV.

ii) Reacting the compound of formula V with an oxidizing compound such as H_2O_2 , peracids and such other oxidizing agents to yield a sulfoxide of formula VI

iii) Reacting the sulfoxide of formula VI with an appropriate iminating agent such as HN_3 , O-substituted hydroxylamines such as O-mesitylenesulfonyl hydroxylamine (MSH) and the like to yield sulfoxamine of formula (IAa);

iv) optionally, compound of formula (IAa) is converted to compound of formula (IA) by suitable agents to get appropriate R_1 group. Alternatively, the compound of formula VI may be converted to compound (IA) by treating with appropriate agents;

v) optionally, if desired, the compound of formula (IAa) or (IA) are converted to pharmaceutically acceptable salts;

The reactions described in the processes (i) to (v) outlined above may be performed by using the methods described herein:

Method A:

The haloketones of formula II may be converted to corresponding cyclic compounds of formula V by reacting with a compound of formula II, through an initial formation of a compound of formula IV, in a solvent such as an alcohol like methanol, ethanol, isopropanol, and the like; acetone, THF, dioxane, acetonitrile, toluene, xylene and the like or a mixture thereof. Reaction temperature may range from ambient to reflux temperature of the solvent(s) used. The compounds of formula IV is converted to respective compound of formula V, by dehydration by refluxing in a suitable medium such as an aqueous alcoholic medium containing a mineral acid such as HCl or H_2SO_4 , or H_3PO_4 ; organic acids such as PTSA may also be used in an organic solvent such as toluene, xylene and the like; organic acid such as acetic acid, propionic acid or trifluoroacetic acid may also be used.

Method B:

The mercapto compounds of formula V may be converted to the respective sulfoxides by reacting with an oxidizing agent. Suitable oxidizing agents may be selected from but not limited to peroxides and peroxyacids and their salts. Suitable oxidizing agent is selected from H_2O_2 , meta-peroxides of Na, K, and the like, oxone®, sodium perborate, sodium tungstate and the like, peracetic acid, m-chloroperbenzoic acid, magnesium monoperoxyphthalate, and the like. Suitable solvents are based on the oxidizing agents used and are selected from water, acetic acid, acetonitrile,

dichloromethane, acetone, THF, methanol, ethanol and the like or a mixture thereof. Reaction temperature may range from -78°C to 40°C , based on the solvent used.

Method C:

- 5 The sulfoxide compounds of formula VI may be converted to sulfoximine compounds by reacting with suitable iminating agents such as hydrazoic acid (HN_3) which may be generated by the reaction of NaN_3 with conc. sulfuric acid in solvents such as CH_2Cl_2 , CHCl_3 and the like. Temperature in the range -10°C to reflux temperature of the solvent(s) used may be used. Alternatively, sulfoxides of formula IV or V may be
- 10 treated with O-substituted hydroxylamines, such as O-mesitylenesulfonylhydroxylamine (MSH), followed by a base such as KOH , NaOH , NaHCO_3 and the like. Solvents such as CH_2Cl_2 , CHCl_3 may be used.

Method D:

- 15 The sulfoximines of formula (IAa) may be converted to corresponding substituted compounds of formula (IA) by reaction with appropriate alkylating/ acylating agents in the presence of a base. The alkylating/acylating agent depends on the desired group R_1 such as suitably substituted alkyl halides/acylhalides or acyl anhydrides. When $\text{R}_1=\text{Me}$, formic acid/formaldehyde mixture is used. Solvents used may be DMF, DMSO,
- 20 acetone, THF, diaoxane, toluene, xylene and the like or a mixture thereof. Bases such as K_2CO_3 , Na_2CO_3 , NaH , KI , $n\text{BuLi}$, Et_3N or a mixture thereof may be used. Reaction temperature may range from 0°C to reflux temperature of the solvent(s) used.

Method E:


- 25 The sulfoxide compounds of formula VI may be directly converted to substituted sulfoximine compounds by reacting with suitable reagents such as Tosylazide, Chloramine T, in solvents such as ethanol, methanol and the like, followed by basification to yield $\text{R}_1=\text{Tosyl}$ groups. Alternatively, reaction with arylamines in the presence of $t\text{-BuOCl}$ gives N-arylsulfoximines.

30

Scheme II:

The compounds of general formula (IB) wherein all the symbols are as defined earlier may be prepared by one or more routes or combinations of reactions outlined in scheme II which comprises:

5



- i) Reacting the compound of general formula VII with atleast two equivalents of an appropriate base followed by treatment with an appropriate ester or anhydride to afford an alcohol of general formula VIII;

10

- ii) heating the compound of general formula VIII in an appropriate solvent in the presence of appropriate acid to get compound of general formula IX.

- iii) Oxidizing compound of formula IX with appropriate oxidizing agents to get a compound of general formula X;
- iv) Reacting sulfoxide of formula X with appropriate agents to afford compound of general formula (IBb);
- 5 v) Optionally compound of formula X may be converted to compound of formula (IB) by suitable agents to get appropriate R¹ group. Alternatively, compound of formula (IBb) may be converted to compound of formula (IB) using appropriate agents.
- 10 vi) Optionally, if desired, compounds of formula (IBb) or (IB) are converted to pharmaceutically acceptable salts;

The reactions described in the processes outlined in the schemes II above may be performed by using the methods described herein:

15 Method F:

The oxime of formula VII may be converted to alcohol of formula VIII by reacting with two equivalents of a suitable base to produce a dianion which is further acylated. Bases such as n-BuLi, Sodium hydride, LDA, LiHMDS, NaHMDS and the like or a mixture thereof may be used. Temperature in the range of -78 °C to ambient
20 temperature may be used. Preferably, the dianion formation is done at -78° to -40°C range. Suitable acylating agents are esters, anhydrides, acyl imidazoles and the like. The reaction is conducted under a blanket of inert atmosphere using inert gases like N₂, He or Ar. Anhydrous condition is very critical for the reaction to give good product and yield.

25 Method G:

The alcohol of formula VIII may be converted to isooxazole of formula IX by dehydration in the presence of an acid. Solvents such as ethanol, THF, toluene, xylene, and the like or a mixture thereof may be used. Suitable acids may be PTSA, H₂SO₄, HCl, HBr, camphorsulfonic acid, pyridinium paratoluene sulfonic acid and the like. The
30 amount of acid used may be catalytic or substoichiometric or stoichiometric to effect the dehydration. Temperature in the range of ambient to reflux temperature of the solvent(s) may be used.

Method B:

The mercapto compound of formula IX may be converted to sulfoxide of formula X by reacting with an oxidizing agent as described in Method B of scheme I earlier.

Method C:

- 5 The sulfoxide compounds of formula X may be converted to sulfoximine compounds of formula (IBb) by reacting with suitable iminating agents as described earlier in Method C of scheme I.

Method D:

- 10 The sulfoximines of formula (IBb) may be converted to compounds of formula (IB) by reaction with appropriate alkylating/acylating agents in the presence of a base as described earlier in method D of scheme I.

Method E:

- 15 The compounds X may be directly converted to compounds of formula (IB) by reacting with suitable reagents as described earlier in Method E of scheme I, such as Tosyl azide, Chloramine T, in solvents such as ethanol, methanol and the like, followed by basification to yield $R_1 = \text{Tosyl}$ groups. Alternatively, reaction with aryl amines in the presence of t-BuOCl gives N-aryl sulfoximines as described in method E of scheme I.


20

25

30

Scheme III

The compound of general formula (IC) wherein all the symbols are as defined earlier may be prepared by a process outlined in scheme III which comprises:



- 5 i. Reacting hydrazine of general formula XI with 1,3-diketone of general formula XII to get compound of general formula XIII;
- ii. Oxidizing compound of formula XIII with appropriate oxidizing agents to get a compound of general formula XIV;
- iii. Reacting sulfoxide of formula XIV with appropriate agents to afford compound of general formula (ICc);
- 10 iv. Optionally compound of formula XIV may be converted to compound of formula (IC) by suitable agents to get appropriate R^1 group. Alternatively, compound of formula (ICc) may be converted to compound of formula (IC) using appropriate agents.

- v. Optionally, if desired, compounds of formula (ICc) or (IC) are converted to pharmaceutically acceptable salts;

The reactions described in the processes outlined in the scheme III above may be performed by using the methods described herein:

5

Method H:

The hydrazone of formula XI or its acid addition salts may be converted to compound of formula XIII by reacting with appropriately substituted 1, 3-diketones of formula XII. Reagents like sodium acetate may be used but not critical. Solvents such as
10 alcohols like, ethanol, methanol, isopropanol and the like, THF, dioxane, toluene, xylene, cyclohexane, heptane, hexane, and the like or mixture thereof may be used. Temperature in the range 20 °C to reflux temperature of the solvent may be used, preferably in the range 60 °C to reflux temperature of the solvent(s) may be used. Inert atmosphere may be maintained using N₂, He, or argon gas.

15

Method B:

The pyrazole compound of formula XIII may be converted to sulfoxide of formula XIV by reacting with an oxidizing agent as described earlier in method B of scheme I.

20

Method C:

The sulfoxide compounds of formula XIV may be converted to sulfoximine compounds of formula (ICc) by reacting with suitable iminating agents as described earlier in method C of scheme I.

25

Method D:

The sulfoximines of (ICc), may be converted to compounds of formula (IC), by reaction with appropriate alkylating/acylating agents in the presence of a base as described earlier in method D of scheme I.

30


Method E:

The compounds XIV may be directly converted to compounds of formula (IC) by reacting with suitable reagents; such as Tosyl azide, Chloramine T, in solvents such as

ethanol, methanol and the like, followed by basification to yield R_1 = Tosyl groups. Alternatively, reaction with aryl amines in the presence of t-BuOCl gives N-aryl sulfoximines as described in method E of scheme I.

5 Scheme IV

The compound of general formula (ID) wherein all the symbols are as defined earlier may be prepared by a process outlined in scheme IV which comprises:



The compound of XV in scheme IV above, may be converted to compound of general formula (ID) defined earlier, by a method which comprises:

- i. Oxidizing compound of XV with appropriate oxidizing agents to get a compound of general formula XVI;
- ii. Reacting sulfoxide of formula XVI with appropriate agents to afford compound of general formula (IDd).
- iii. Optionally compound of formula (IDd) obtained in ii) above may be converted to compound of formula (ID) by suitable agents to get appropriate R^1 group.

- iv. Optionally, compound of formula XVI may be directly converted to compound of formula (ID) using appropriate reagents.
- v. Optionally, if desired, compound of formula (IDd) or (ID) may be converted to pharmaceutically acceptable salts;

5

The compound of general formula (ID) may be prepared by a process outlined in scheme IV which comprises:

Method B:

10

The lactone compound of formula XV may be converted to sulfoxide of formula XVI by reacting with an oxidizing agent as described earlier in method B of scheme I.

Method C:

15

The sulfoxide compounds of formula XVI may be converted to sulfoximine compounds of formula (IDd) by reacting with suitable iminating agents as described earlier in method C of scheme I.

Method D:

20

The sulfoximines of (IDd) may be converted to compounds of formula (ID), by reaction with appropriate alkylating/acylating agents in the presence of a base as described earlier in method D of scheme I.


Method E:

25

The compounds XVI may be directly converted to compounds of formula (ID) by reacting with suitable reagents; such as Tosyl azide, Chloramine T, in solvents such as ethanol, methanol and the like, followed by basification to yield $R_1 =$ Tosyl groups. Alternatively, reaction with aryl amines in the presence of t-BuOCl gives N-aryl sulfoximines as described in method E of scheme I.

30 Scheme V

The compound of general formula (IE) wherein all the symbols are as defined earlier may be prepared by a process outlined in scheme V which comprises:



- i. Reacting compound of formula XVII, with a compound of formula XVIII to get the compound of formula XIX;
- 5 ii. Oxidizing compound of XIX with appropriate oxidizing agents to get a compound of general formula XX;
- iii. Reacting sulfoxide of formula XX with appropriate agents to afford compound of general formula (IEe);
- iv. Optionally compound of formula (IEe) obtained in iii) above may be converted to
10 compound of formula (IE) by suitable agents to get appropriate R^1 group.

- v. Optionally, compound of formula XX may be directly converted to compound of formula (IE) using appropriate reagents.
- vi. Optionally, if desired, compound of formula (IEe) or (IE) may be converted to pharmaceutically acceptable salts;

5

The compound of general formula (IE) may be prepared by a process outlined in scheme V which comprises:

Method I:

10

The keto compound of the formula XVII, may be converted to compound of formula XIX by reacting with compound of formula XVIII. Reagents like ammonium acetate may be used. Reaction may be carried out using solvents like propionic acid or without using solvent. Reaction temperatures may range between ambient and 150°C or reflux temperature of the solvent(s) used.

15

Method B:

The pyridine compound of formula XIX may be converted to sulfoxide of formula XX by reacting with an oxidizing agent as described earlier in method B of scheme I.

20

Method C:

The sulfoxide compounds of formula XX may be converted to sulfoximine compounds of formula (IEe) by reacting with suitable iminating agents as described earlier in method C of scheme I.

25

Method D:

The sulfoximines of (IEe), may be converted to compounds of formula (IE), by reaction with appropriate alkylating/acylating agents in the presence of a base as described earlier in method D of scheme I.

30


Method E:

The compounds XX may be directly converted to compounds of formula (IE) by reacting with suitable reagents; such as Tosyl azide, Chloramine T, in solvents such as

ethanol, methanol and the like, followed by basification to yield R_1 = Tosyl groups. Alternatively, reaction with aryl amines in the presence of t-BuOCl gives N-aryl sulfoximines as described in method E of scheme I.

5 Scheme VI

The compound of general formula (IF) wherein all symbols are as defined earlier may be prepared by a process outlined in scheme VI which comprises:



10

- Reacting hydrazine of general formula XXII with 1,3-diketone of general formula XXI to get compound of general formula XXIII;
- Oxidizing compound of formula XXIII with appropriate oxidizing agents to get a compound of general formula XXIV;

- iii. Reacting sulfoxide of formula XXIV with appropriate agents to afford compound of general formula (If);
- iv. Optionally compound of formula XXIV may be converted to compound of formula (If) by suitable agents to get appropriate R^1 group. Alternatively, compound of formula (If) may be converted to compound of formula (If) using appropriate agents.
- v. Optionally, if desired, compounds of formula (If) or (If) are converted to pharmaceutically acceptable salts;

The reactions described in the processes outlined in the scheme VI above may be performed by using the methods described herein:

Method H:

The hydrazene of formula XXII or its acid addition salts may be converted to compound of formula XXIII by reacting with appropriately substituted 1, 3-diketones of formula XXI. Reagents like sodium acetate may be used but not critical. Solvents such as alcohols like, ethanol, methanol, isopropanol and the like, THF, dioxane, toluene, xylene, cyclohexane, heptane, hexane, and the like or mixture thereof may be used. Temperature in the range 20 °C to reflux temperature of the solvent may be used, preferably in the range 60 °C to reflux temperature of the solvent(s) may be used. Inert atmosphere may be maintained using N_2 , He, or argon gas.

Method B:

The pyrazole compound of formula XXIII may be converted to sulfoxide of formula XXIV by reacting with an oxidizing agent as described earlier in method B of scheme I.

Method C:

The sulfoxide compounds of formula XXIV may be converted to sulfoximine compounds of formula (If) by reacting with suitable iminating agents as described earlier in method C of scheme I.

Method D:

The sulfoximines of (If), may be converted to compounds of formula (If), by reaction with appropriate alkylating/acylating agents in the presence of a base as described earlier in method D of scheme I.

Method E:

5 The compounds XXIV may be directly converted to compounds of formula (If) by reacting with suitable reagents; such as Tosyl azide, Chloramine T, in solvents such as ethanol, methanol and the like, followed by basification to yield R_1 = Tosyl groups. Alternatively, reaction with aryl amines in the presence of t-BuOCl gives N-aryl sulfoximines as described in method E of scheme I.

10 Pharmaceutically acceptable salts forming part of this invention are intended to define but not limited to salts of the carboxylic acid moiety when present in the molecule such as alkali metal salts like Li, Na, and K salts; alkaline earth metal salts like Ca and Mg salts; salts of organic bases such as lysine, arginine, guanidine and its derivatives, which may be optionally substituted, diethanolamine, choline, tromethamine and the
15 like; ammonium or substituted ammonium salts and aluminium salts. Salts may be acid addition salts which defines but not limited to sulfates, bisulfates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, fumarates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates
20 and the like. Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.

It will be appreciated that in any of the above mentioned reactions any reactive group in the substrate molecule may be protected, according to conventional chemical practice. Suitable protecting groups in any of the above mentioned reactions are those used
25 conventionally in the art. The methods of formation and removal in such protecting groups are those conventional methods appropriate to the molecule being protected. T. W. Greene and P. G. M. Wuts "Protective groups in Organic Synthesis", John Wiley & Sons, Inc, 1999, 3rd Ed., 201-245 along with references therein.

Acid addition salts, wherever applicable may be prepared by treatment with acids such as
30 tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and the like

in solvents such as water, alcohols, ethers, ethyl acetate, dioxane, THF, acetonitrile, DMF or a lower alkyl ketone such as acetone, or mixtures thereof.

Another aspect of the present invention comprises a pharmaceutical composition, containing at least one of the compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their
5 pharmaceutically acceptable solvates thereof as an active ingredient, together with pharmaceutically employed carriers diluents and the like.

Pharmaceutical compositions containing a compound of the present invention may be prepared by conventional techniques, e.g. as described in Remington: the Science
10 and Practice of Pharmacy, 19th Ed., 1995. The compositions may be in the conventional forms, such as capsules, tablets, powders, solutions, suspensions, syrups, aerosols or topical applications. They may contain suitable solid or liquid carriers or in suitable sterile media to form injectable solutions or suspensions. The compositions may contain
15 0.5 to 20 %, preferably 0.5 to 10 % by weight of the active compound, the remaining being pharmaceutically acceptable carriers, excipients, diluents, solvents and the like.

Due to their mixed COX-1/COX-2 activity, the compounds of formula (I) represent good anti-inflammatory compounds having less harmful side effects than the NSAIDs as well as selective COX-2 inhibitors.

The present invention provides a compound of formula (I) for use in a method of
20 treatment of the human or animal body by therapy, in particular for the treatment of pain, fever or inflammation, to inhibit prostanoid-induced smooth muscle contraction or for the prevention of colorectal cancer.

Another objective of the present invention is to provide for the use of compound of formula (I) in the manufacture of a medicament for the treatment of pain, fever or
25 inflammation, to inhibit prostanoid-induced smooth muscle contraction or for the prevention of colorectal cancer.

The compounds of the present invention are useful in the treatment of inflammation and inflammation related disorders by administering the subject a therapeutic amount of the compound of formula-I or its active salt. Inflammation is
30 associated with a variety of disease conditions. A list of such disease conditions which can be treated by cyclooxygenase inhibitors and COX-2 inhibitors in particular, are disclosed in US 5604,253 and 5908,852 and WO 9638442, 9603392 and WO 9714691. Such conditions includes pain, fever and inflammation of a variety of conditions

including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhoea, headache, toothache, sprains and strains, menstrual cramps, premature labor, Such compounds may also be used in the treatment of arthritis, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis. They may also be used in the treatment of skin inflammation disorders such as psoriasis, eczema, burning and dermatitis.

The compounds of formula (I) can also be used as alternative to conventional NSAIDs, particularly where such non-steroidal anti-inflammatory drugs may be contraindicated such as the treatment of patients with gastrointestinal disorders including peptide ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis, Crohn's disease, inflammatory bowel syndrome and irritable bowel syndrome, ulcerative colitis, Crohn's disease, gastrointestinal bleeding and coagulation disorders, kidney disease (e.g. impaired renal function), those prior to surgery or taking anticoagulants, and those susceptible to NSAIDs.

In addition, compounds of the present invention may inhibit cellular neoplastic transformations and metastatic tumour growth and hence useful in the treatment of cancer. In particular, the present invention provides for a method for treating neoplasia that produces prostaglandin by treating the subject to a therapeutic amount of the compound (I). Thus the compounds of the present invention would be useful for the prevention and treatment of cancer, such as colorectal cancer and cancer of the lip, mouth, esophagus, breast, lung, prostate, bladder, pancreas, cervix and skin, small bowel cancer, stomach cancer ovary cancer, cervical cancer and the like. Use of COX-2 inhibitors in aforesaid diseases are discussed in US 5972,986 and WO 0076983 & 9714691. Such compounds will also be useful in the treatment of inflammation in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, nephritis, hypersensitivity, swelling after injury, myocardial ischemia and the like. The compounds would also be useful in the treatment of ophthalmic diseases such as retinitis, retinopathies, uveitis, ocular photophobia, and of

acute injury to the eye tissue. They are also useful in the treatment of pulmonary inflammation, such as that associated with viral infections and cystic fibrosis.

The compounds of the present invention would also be useful for the treatment of certain central nervous system disorders, such as cortical dementias including Alzheimer's disease (*Bratisl Lek Listy* 2001; 102 (3): 123-132) and central nervous system damage resulting from stroke, ischemia and trauma. These compounds will also be use in alleviating neuropathic pain. The compounds of the invention are useful as anti-inflammatory agents, such as for the treatment of arthritis, with the additional benefit of having significantly less harmful side effects. These compounds would be useful in the treatment of allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome and atherosclerosis.

The compounds of the present invention may also be useful in the treatment of angiogenesis-mediated disorders. Angiogenesis mediated disorders may be treated with cyclooxygenase inhibitors are described in U.S. 6025,353 and WO 0076983. According to these patents such disorders include, for example, metastasis, corneal graft rejection, ocular neovascularization, diabetic retinopathy, retrolental fibroplasia, neovascular glaucoma, gastric ulcer, infantile hemangiomas, angiofibroma of the nasopharynx, avascular necrosis of the bone and endometriosis.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals including mammals, rodents, and the like. More preferred animals include horses, dogs and cats.

The present compounds may also be used as co-therapies, partially or completely, in place of other conventional anti-inflammants like steroids, NSAIDs, 5-lipoxygenase inhibitors, LTB₄ receptor antagonists and LTA₄ hydrolase inhibitors. They can also be used in combination therapies with opioids and other analgesics, including narcotic analgesics, Mu receptor antagonists, Kappa receptor antagonists, non-narcotic analgesics, monoamine uptake inhibitors, adenosine regulating agents, cannabinoid derivatives, substance P antagonists, neurokinin-1 receptor antagonists and sodium channel blockers among others.

The present invention also relates to a pharmaceutical composition for the treatment of a disorder or condition that can be treated by inhibition COX in a mammal, preferably a human, cat, livestock or dog, comprising a COX inhibiting effective amount

of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

5 The present invention also relates to a method for treating a disorder or condition that can be treated or prevented by inhibiting COX in a mammal, preferably a human, cat, dog livestock, comprising administering to a mammal requiring such treatment a COX inhibiting effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

10 This invention also relates to a method of or a pharmaceutical composition for the treatment of inflammation and similar diseases which comprises administering a compound of formula (I) of this invention or its salt to a mammal including a human, cat, livestock or dog. The said inhibitory compound is used in combination with one or more other therapeutically active agents such as:

- 15 A) In a condition where a joint has become inflamed along with a bacterial, fungal, protozoal, and/or viral infection, said inhibitory compound is administered in combination with one or more antibiotic, antifungal, antiprotozoal, and/or antiviral therapeutic agents.
- 20 i) During multi-fold treatment of pain and inflammation is required, the compound should be administered in combination with inhibitors of other mediators of inflammation, consisting of members of the following groups: NSAIDS, H₁-receptor antagonists, kinin-B₁- and B₂ - receptor antagonists; prostaglandin inhibitors selected from the group consisting of PGD-, PGF- PGI₂-, and PGE-receptor antagonists; thromboxane A₂ (TXA₂-) inhibitors; 5-, 12- and 15-lipoxygenase inhibitors; leukotriene LTC₄-, LTD₄/LTE₄-, and LTB₄-inhibitors; PAF-receptor antagonists; anti-inflammatory glucocorticoids; anti-gout agents including colchicine; 25 xanthine oxidase inhibitors including allopurinol; and uricosuric agents selected from probenecid, sulfinpyrazone, and benzbromarone.

B) When treating older mammals with geriatric disorders, the said compound is administered in combination with members selected from any of the following groups: cognitive therapeutics, anti-hypertensives and other cardiovascular drugs
5 selected from among diuretics, vasodilators, β -adrenergic receptor antagonists, ACE inhibitors alone or in combination with neutral endopeptidase inhibitors intending to offset the consequences of atherosclerosis, hypertension, myocardial ischemia, angina, congestive heart failure, and myocardial infarction

10 For the treatment of any of the above-mentioned diseases the compounds of formula (I) may be administered, for example, orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.

The compounds of the present invention is useful in the treatment of
15 inflammatory diseases caused by cytokines, specially, TNF- α , by either inhibiting the production or by inhibiting the TNF- α converting enzyme (TACE) or by inhibiting TNF- α itself.

In general, the dosage for humans will range preferentially from 0.01 mg to 100 mg per kg of body weight per day, although variations will occur, depending upon the
20 weight, sex and condition of the subject being treated, the state of the disease being treated and the particular route of administration. However, the preferred dosage level should be in the range of from 0.1 mg to 10 mg per kg of body weight per day in single or divided dosage.

For non-human mammals e.g. dogs, cats, horses or other livestock the dosage
25 should be from about 0.01 mg/g to about 20.0 mg/kg/day, and more preferably from about 0.5 mg/kg to about 8.0 mg/kg/day.

The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the routes as previously indicated, in single or multiple doses. More specifically, the novel compounds
30 described in the invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, trochees, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous

suspensions, injectable solutions, elixirs, syrups, and the like. The carriers may include solid diluents or fillers, sterile aqueous media and various nontoxic organic solvents etc. Moreover, for oral consumption, the pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds as described in the invention are present in the compositions at concentration levels ranging from 5% to 60% by weight, preferably 10% to 50% by weight.

For oral administration, the tablets may be combined with various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dipotassium phosphate and glycine along with various disintegrants such as starch more preferably corn, potato or tapioca starch, alginic acid, sodium carbonate and certain complex silicates; together with binders like polyvinylpyrrolidone, sucrose, gelatin and acacia, humectants such as for example, glycerol; solution retarding agents, such as, for example paraffin; absorption accelerators such as, for example, quaternary ammonium compounds; wetting agents like cetyl alcohol and glycerol monostearate; absorbents like kaolin and bentonite clay. Additionally, magnesium stearate, sodium lauryl sulfate, talc, calcium stearate, solid polyethylene glycols and mixtures thereof are often added as lubricating agents for tableting purposes. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Similar type of solid compositions may also be employed as fillers and excipients in soft and hard gelatine capsules; preferred materials include lactose, milk sugar or high molecular weight polyethylene glycols.

The active compounds can also be in micro-encapsulated form using one or more of the excipients noted above. The solid dosage forms of tablets, dragees, capsules, pills, and the granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings which are well known in the field of pharmaceutical formulation art. In such solid dosage forms the active compound may be admixed with atleast one inert diluent such as sucrose, lactose and starch. They may also contain, additional substances for e.g. tableting lubricants and other substances like magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the formulation may also contain buffering agents. They may also be so formulated that they release the active ingredient(s) only or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. The same may be achieved using embedded agents like, for example, polymeric substances and waxes.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. For such oral consumption it is desirable to combine the active ingredient with various sweetening or flavoring agents, coloring matter or dyes, if so desired. The diluents may be selected from water, ethanol, propylene glycol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3 butylene glycol, dimethyl formamide, oils for e.g. cottonseed, groundnut, corn, germ, olive, castor, sesame oils and the like, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and esters of fatty acids like sorbitan and various combination thereof. For mammals other than humans, the composition of the active substance are suitably modified.

For parenteral administration, the solutions of the compound is prepared in either sesame or peanut oil or in aqueous propylene glycol. The aqueous solutions should be suitably buffered if necessary, and the diluent should be first rendered isotonic. The aqueous solutions are suitable for intravenous injection purposes while the oily solutions are suitable for intra-articular, intra-muscular and subcutaneous injection purposes. The aforesaid compositions can be readily prepared under sterile conditions following well known standard pharmaceutical techniques by persons skilled in the art.

The compounds of formula (I) may also be administered in the form of suppositories for rectal or vaginal administration of the active ingredient. These compositions can be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at room temperature (for example, 10 °C to 32 °C) but liquid at the rectal temperature and will melt in the rectum or vagina to release the active ingredient. Such materials are polyethylene glycols, cocoa butter, suppository and wax.

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

For transdermal and topical administration, the dosage forms will include ointments, pastes, creams, lotions, gels, powders, solutions, sprays and inhalants. Transdermal patches may be prepared following standard drug delivery techniques and applied to the skin of a mammal, preferably a human or a dog, to be treated. Ophthalmic solutions, ear drops, eye ointments, powders can also be used as a medium of providing therapeutic dosages to the patients as will be necessary.

The ointments, pastes, creams and gels may, in addition to the active ingredient, contain excipients like animal and vegetable fats, oils, waxes, paraffins, starch,

tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, zinc oxide or their mixtures.

Powders and sprays may contain, in addition to the active substance, excipients like lactose, talc, silicic acid, aluminium hydroxide, calcium silicates and polyamide powder, or their mixtures. Sprays will additionally contain propellants like chlorofluorohydrocarbons.

The compounds of the present invention have been tested for their biological activities by carrageenan foot pad edema test in male as well as female Wistar rats according to standard protocol described in literature (Winter *et. al*, *Proc. Soc. Exp. Biol. Med.*, 111, 544, (1962) ; Otterness and Bliven, Laboratory Models for Testing NSAIDS, in Non-Steroidal Anti-inflammatory Drugs, (J. Lombardino, ed.1985)). The protocol followed was as described below:

Wistar rats obtained from the Experimental Animal Facility of Zydus Research Centre. Animals were housed in an environmentally controlled rooms with food and water available ad-libitum. All the experimental protocols were approved by the Institutional Animal Ethics Committee. Animals were divided into different groups, each group comprising of five-six animals. After an overnight fast, animals of the control group received vehicle only by oral gavage whereas animals of the other groups received different doses of the test substance(s). Each rat received same volume of the formulation i.e. 2 ml/kg on body weight basis. One hour after administration of the vehicle or test substance, all the animals received sub-planter injection of carrageenan (1 % w/v in saline). Paw volume was measured at 0, 1, 3 and 5 hour after carrageenan injection. Anti-inflammatory activity, expressed as % Inhibition in paw swelling was calculated by measuring change in paw volume at different time intervals after carrageenan injection vs corresponding 0 hr values using the following formula.

$$\% \text{ inhibition} = \frac{(\text{PVC} - \text{PVT})}{\text{PVC}} \times 100$$

Where

PVC = Average change in Paw volume of control animals

PVT = Average change in Paw volume of treated animals.

The compounds of the present invention inhibited 10 % - 95 % rat paw edema at a dose of 30 mg/kg. The compounds of the present invention possess analgesic property and is effective in neuropathy pain. The compounds of the present invention inhibit the COX-1 and COX-2 coenzymes to varying extents as found by human whole blood assay (C.

5 Brideau, S. Kargman, S.Liu; *Inflammation Research*, 45, 68-74 (1996))

The inhibitory activities of representative compounds of the present invention are given in the following table:

Sl. No.	Compound No.	Dose (mg/kg)	% Inhibition of paw edema	
			1 hour	3 hour
1.	179	30	54	41
2.	171	30	50	25
3.	154	30	46	47
4.	97	30	13	36
5.	153	30	42	43
6.	158	30	44	26
7.	187	30	33	29
8.	112	30	57	40
9.	Celecoxib	30	33	26

10

The invention is explained in detail by the examples given below, which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.


15

¹H NMR spectral data given in the tables (vide infra) are recorded using a 300 MHz spectrometer (Bruker AVANCE-300) and reported in δ scale. Until and otherwise mentioned the solvent used for NMR is CDCl₃ using Tetramethyl silane as the internal standard.

20

Preparation 1

5-(3-Fluoro-4-methoxyphenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H-pyrazole (Compound No.14)



Step1: Preparation of N-*tert*-butoxycarbonyl-N-(4-methylsulfanyl)phenyl hydrazine


A mixture of 4-methylsulfanyliodobenzene (10 g), *tert*-butylcarbazate (5.2 g), cesium carbonate (18.2 g), copper iodide (80 mg) and 1,10-phenanthroline (576 mg) in DMF (30 mL) was stirred at 90 °C for 18 h under nitrogen atmosphere. The reaction mixture was chromatographed over silicagel, using 5 % ethyl acetate in petroleum ether as eluent to afford 6.2 g of product as a thick liquid.

Step2: Preparation of 5-(3-fluoro-4-methoxyphenyl)-1-(4-methylsulfanylphenyl)-3-trifluoromethyl-1H-pyrazole.

A mixture of 1-(3-fluoro-4methoxyphenyl)-4,4,4-trifluoro butane-1,3-dione (1.0 g) and N-*tert*-butoxycarbonyl-N-(4-methylthio)phenyl hydrazine (0.9 g) (obtained in step1 above) in ethanolic HCl (25 mL, 12 %) was refluxed for 24 h. Solvent was evaporated under reduced pressure. Water (50 mL) was added to the residue and extracted with diethyl ether (3X50 mL). The organic extract was washed with water (2 X 50 mL), brine (50 mL), dried over sodium sulphate and evaporated under reduced pressure. The product obtained was chromatographed over silicagel, using 2 % ethyl acetate in petroleum ether as eluent to afford 820 mg of product as a thick liquid.










In like manner the following compounds in table 1 were prepared following the procedure described above:










Table 1















25

	X ₂	X ₁	R ₄	R ₃	Mol. Wt	% Yield

1.	H	H	CF ₃		Mol. Wt. = 352	% Yield = 34
	¹ H: 2.49(3H, s), 6.7(1H, s), 7.0(2H, t, J=8.7 Hz), 7.2(6H, m).					
2.	H	H	CF ₃		Mol. Wt. = 368.5	% Yield = 62
	¹ H: 2.5(3H, s), 6.7(1H, s), 7.15(2H, d, J=8.5 Hz), 7.2(4H, m), 7.3(2H, d, J=8.5 Hz).					
3.	H	H	CF ₃		Mol. Wt. = 348	% Yield = 50
	¹ H: 2.3(3H, s), 2.48(3H, s), 6.7(1H, s), 7.1(4H, m), 7.13(3H, m), 7.3(1H, m).					
4.	H	H	CF ₃		Mol. Wt. = 364	% Yield = 67
	¹ H: 2.4(3H, s), 3.8(3H, s), 6.67(1H, s), 6.8(2H, d, J=8.8 Hz), 7.1(2H, d, J=8.8 Hz), 7.2(4H, m).					
5.	H	H	CF ₃		Mol. Wt. = 392	% Yield = 46
	¹ H: 1.0(3H, t, J=5.7 Hz), 1.8(2H, m), 2.4(3H, s), 3.9(2H, t, J=6.5 Hz), 6.6(1H, s), 6.8(2H, d, J=6.7 Hz), 7.1(2H, d, J=6.6 Hz), 7.2(4H, d, J=2.3 Hz).					
6.	H	H	CF ₃		Mol. Wt. = 378	% Yield = 82
	¹ H: 1.4(3H, t, J=6.9 Hz), 2.4(3H, s), 4.0(2H, q, J=6.9 Hz), 6.6(1H, s), 6.8(2H, d, J=8.7 Hz), 7.1(2H, d, J=8.7 Hz), 7.2(4H, m).					
7.	H	H	CF ₃		Mol. Wt. = 392	% Yield = 69
	¹ H: 1.3(6H, d, J=6.0 Hz), 2.48(3H, s), 4.5(1H, m), 6.6(1H, s), 6.8(2H, d, J=6.6 Hz), 7.1(2H, d, J=8.7 Hz), 7.2(4H, m).					
8.	H	H	CF ₃		Mol. Wt. = 386.5	% Yield = 50
	¹ H: 2.5(3H, s), 6.7(1H, s), 7.1(2H, m), 7.2(3H, m), 7.3(2H, dd, J=6.8 & 2.2 Hz).					
9.	H	H	CF ₃		Mol. Wt. = 370	% Yield = 88
	¹ H: 2.5(3H, s), 6.7(1H, s), 6.9 - 7.25(7H, complex).					


10.	H	H	CF ₃		Mol. Wt. = 366	% Yield = 53
	¹ H: 2.2(3H, s), 2.4(3H, s), 6.7(1H, s), 6.9(2H, d, J=7.4 Hz), 7.1(1H, d, J=7.2 Hz), 7.2(4H, m).					
11.	H	H	CF ₃		Mol. Wt. = 378	% Yield = 58
	¹ H: 1.57(3H, s), 2.49(3H, s), 3.9(3H, s), 6.7(1H, s), 6.8(1H, d, J=8.7 Hz), 6.9(1H, dd, J=2.1 & 8.7 Hz), 7.2(4H, m), 7.3(1H, d, J=2.1 Hz).					
12.	H	H	CF ₃		Mol. Wt. = 398.5	% Yield = 57
	¹ H: 2.49(3H, s), 3.9(3H, s), 6.7(1H, s), 6.8(1H, d, J=8.7 Hz), 6.9-7.0(1H, dd, J=2.4 & 8.7 Hz), 7.2(4H, m), 7.3(1H, d, J=2.4 Hz).					
13.	H	H	CF ₃		Mol. Wt. = 443	% Yield = 55
	¹ H: 2.49(3H, s), 3.9(3H, s), 6.7(1H, s), 6.8(1H, d, J=7.8 Hz), 7.0(1H, dd, J=2.1 & 8.5 Hz), 7.2(4H, m), 7.5(1H, d, J=2.6 Hz).					
14.	H	H	CF ₃		Mol. Wt. = 382	% Yield = 56.5
	¹ H: 2.49(3H, s), 3.9(3H, s), 6.7(1H, s), 6.8-6.9(3H, m), 7.2(4H, m).					
15.	H	H	CF ₃		Mol. Wt. = 378	% Yield = 50.3
	¹ H: 2.2(3H, s), 2.48(3H, s), 3.6(3H, s), 6.6(1H, s), 6.7(2H, m), 7.0(1H, d, J=7.5 Hz), 7.2(4H, m).					
16.	H	F	CF ₃		Mol. Wt. = 382	% Yield = 74
	¹ H: 2.8(3H, s), 3.8(3H, s), 6.7(1H, s), 6.8(2H, dd, J=8.8 & 2.14 Hz), 6.9(2H, dd, J=10.4 & 2.01 Hz), 7.15(2H, dd, J=8.85 & 2.1 Hz), 7.4(1H, t, J=8.0 Hz).					
17.	F	H	CF ₃		Mol. Wt. = 382	% Yield = 66
	¹ H: 2.4(3H, s), 3.8(3H, s), 6.67(1H, s), 6.8(2H, d, J=8.8 Hz), 7.1(2H, m), 7.17(3H, m).					
18.	H	H	CF ₃		Mol. Wt. = 334	% Yield = 59
	¹ H: 2.48(3H, s), 6.7(1H, s), 7.23(4H, m), 7.3(5H, m).					

19.	H	H	CH ₃		Mol. Wt. = 310	% Yield = 42.6
	¹ H: 2.23(3H, s), 2.46(3H, s), 3.74(3H, s), 6.3(1H, s), 6.9(2H, d, J=8.8 Hz), 7.1(4H, m), 7.25(2H, d, J=8.67 Hz).					
20.	H	H	CF ₃		Mol. Wt. = 379	% Yield = 77
	¹ H: 2.5(3H, s), 6.8(1H, s), 7.2(4H, m), 7.4(2H, d, J=8.9 Hz), 8.2(2H, d, J=8.9 Hz).					
21.	H	H	CF ₃		Mol. Wt. = 364	% Yield = 71
	¹ H: 2.48(3H, s), 3.7(3H, s), 6.7-6.8(3H, m), 6.9(1H, m), 7.3(5H, m).					
22.	H	H	CF ₃		Mol. Wt. = 400	% Yield = 73.6
	¹ H: 2.5(3H, s), 4.0(3H, s), 6.7(1H, s), 6.79(2H, d, -J=8.6 Hz), 7.24(4H, m).					
23.	H	H	CF ₃		Mol. Wt. = 380	% Yield = 98.5
	¹ H: 2.5(3H, s), 3.9(3H, s), 5.7(1H, s, -OH), 6.4-6.8(4H, m), 7.1-7.2(4H, m).					
24.	H	H	COOH		Mol. Wt. = 340	% Yield = 90
	¹ H: 2.49(3H, s), 3.82(3H, s), 6.8(2H, d, J=8.76 Hz), 7.0(1H, s), 7.1(2H, d, J=8.76 Hz), 7.26(4H, m)					
25.	H	H	CH ₂ OH		Mol. Wt. = 326	% Yield = 85.5
	¹ H: 2.0(1H, t, OH), 2.48(3H, s), 3.8(3H, s), 4.8(2H, m), 6.4(1H, s), 6.8(2H, dd, J=8.8 & 3.5 Hz), 7.1(2H, d, J=8.7 Hz), 7.14-7.3(4H, m).					
26.	H	H	CF ₃		Mol. Wt. = 394	% Yield = 53
	¹ H: 2.48(3H, s), 3.98(2H, m), 4.0(2H, m), 6.68(1H, s), 6.88(2H, d, J=8.85 Hz), 7.1(2H, d, J=8.9 Hz), 7.2(4H, m)					
27.	H	H	CF ₃		Mol. Wt. = 335	% Yield = 25.9
	¹ H: 2.55(3H, s), 7.18(1H, s), 7.3(2H, dd, J=6.7 & 2.1 Hz), 7.4(2H, d, J=8.6 Hz), 7.7(2H, dd, J=4.5 & 1.5 Hz), 8.7(2H, dd, J=4.6 & 1.5 Hz).					

28.	H	H	CF ₃		Mol. Wt. = 335	% Yield = 61.3
¹ H: 2.54(3H, s), 6.8(1H, s), 7.2(4H, m), 7.4(1H, m), 8.2(1H, m), 8.5(1H, d, J=2.0 Hz), 9.0(1H, d, J=1.5 Hz).						
29.	H	H	CF ₃		Mol. Wt. = 335	% Yield = 27.8
¹ H: 2.54(3H, s), 7.3(1H, dd, J=6.0 & 1.0 Hz), 7.35(2H, d, J=8.6 Hz), 7.48(3H, m), 7.7(1H, m), 8.0(1H, d, J=7.9 Hz), 8.6(1H, m).						
30	H	H	CF ₃		Mol. Wt. = 340	% Yield = 45
¹ H: 2.54(3H, s), 6.7(1H, s), 6.8(1H, dd, J=3.57 & 1.05 Hz), 6.9(1H, dd, J=5.0 & 3.6 Hz), 7.28(4H, m), 7.33(1H, dd, J=5.0 & 1.0 Hz).						

Preparation 2

5-(3-Fluoro-4-methoxyphenyl)-1-(4-methylsulfinylphenyl)-3-trifluoromethyl-1H-pyrazole. (Compound No.44)



5

To a solution of 5-(3-fluoro-4-methoxyphenyl)-1-(4-methylsulfinylphenyl)-3-trifluoromethyl-1H-pyrazole (compound No.14) (790 mg) in chloroform (25 mL), m-chloroperbenzoic acid (55-75 %, 464 mg) was added in one portion at -40 °C and stirred at the same temperature for one hour. The reaction mixture was diluted with chloroform (50 mL), washed with saturated solution of aqueous sodium bicarbonate (30 mL), water (2 X 30 mL), dried over calcium chloride and evaporated under reduced pressure. The product obtained was chromatographed over silicagel using 7:3 ethyl acetate: petroleum ether as eluent to afford 600 mg of product as a thick liquid.

In like manner compounds in the table 2 were prepared following the procedure described above:


































Table 2:

	X ₂	X ₁	R ₄	R ₃	Mol. Wt	% Yield
31.	H	H	CF ₃		Mol. Wt. = 368	% Yield = 59
	¹ H: 2.7(3H, s), 6.7(1H, s), 7.0(2H, t, J=8.7 Hz), 7.2(2H, m), 7.4(2H, d, J=8.7 Hz), 7.6(2H, d, J=8.7 Hz).					
32.	H	H	CF ₃		Mol. Wt. = 384.5	% Yield = 53
	¹ H: 2.7(3H, s), 6.7(1H, s), 7.1(2H, d, J=8.5 Hz), 7.3(2H, d, J=8.5 Hz), 7.4(2H, d, J=6.4 Hz), 7.6(2H, d, J=8.6 Hz).					
33.	H	H	CF ₃		Mol. Wt. = 364	% Yield = 70
	¹ H: 2.3(3H, s), 2.7(3H, s), 6.7(1H, s), 7.11(2H, d, J=8.1 Hz), 7.16(2H, d, J=8.1 Hz), 7.49(2H, d, J=8.5 Hz), 7.6(2H, d, J=8.5 Hz).					
34.	H	H	CF ₃		Mol. Wt. = 380	% Yield = 63
	¹ H: 2.7(3H, s), 3.8(3H, s), 6.7(1H, s), 6.8(2H, d, J=8.7 Hz), 7.1(2H, d, J=8.7 Hz), 7.5(2H, d, J=8.5 Hz), 7.6(2H, d, J=8.9 Hz).					
35.	H	H	CF ₃		Mol. Wt. = 408	% Yield = 87
	¹ H: 1.0(3H, t, J=7.4 Hz), 1.8(2H, m), 2.7(3H, s), 3.9(2H, t, J=6.5 Hz), 6.7(1H, s), 6.8(2H, d, J=6.7 Hz), 7.1(2H, d, J=6.7 Hz), 7.4(2H, d, J=6.6 Hz), 7.6(2H, d, J=6.6 Hz).					
36.	H	H	CF ₃		Mol. Wt. = 394	% Yield = 84
	¹ H: 1.4(3H, t, J=6.9 Hz), 2.7(3H, s), 4.0(2H, q, J=6.9 Hz), 6.7(1H, s), 6.8(2H, d, J=8.8 Hz), 7.1(2H, d, J=8.8 Hz), 7.5(2H, d, J=8.6 Hz), 7.6(2H, d, J=8.6 Hz).					
37.	H	H	CF ₃		Mol. Wt. = 408	% Yield = 68
	¹ H: 1.3(6H, d, J=6.1 Hz), 2.7(3H, s), 4.5(1H, m), 6.7(1H, s), 6.8(2H, d, J=8.9 Hz), 7.1(2H, d, J=9.0 Hz), 7.5(2H, d, J=8.7 Hz), 7.6(2H, d, J=8.9 Hz).					
38.	H	H	CF ₃		Mol. Wt. = 402.5	% Yield = 64
	¹ H: 2.7(3H, s), 6.7(1H, s), 7.1(2H, m), 7.3(1H, dd, J=8.9 & 2.1 Hz), 7.5(2H, d, J=8.67 Hz), 7.7(2H, d, J=8.7 Hz).					


39.	H	H	CF ₃		Mol. Wt. = 386	% Yield = 65
¹ H: 2.7(3H, s), 6.78(1H, s), 7.1(3H, m), 7.5(2H, d, J=8.6 Hz), 7.7(2H, d, J=8.3 Hz).						
40.	H	H	CF ₃		Mol. Wt. = 382	% Yield = 65
¹ H: 2.2(3H, s), 2.7(3H, s), 6.7(1H, s), 6.9(2H, m), 7.1(1H, m), 7.4(2H, d, J=8.7 Hz), 7.6(2H, d, J=8.6 Hz).						
41.	H	H	CF ₃		Mol. Wt. = 394	% Yield = 78
¹ H: 2.1(3H, s), 2.7(3H, s), 3.8(3H, s), 6.7(1H, s), 6.73(1H, d, J=8.3 Hz), 6.9(1H, dd, J=2.1 & 8.1 Hz), 7.0(1H, d, J=2.4 Hz), 7.5(2H, d, J=8.5 Hz), 7.6(2H, d, J=8.3 Hz).						
42.	H	H	CF ₃		Mol. Wt. = 414.5	% Yield = 80.5
¹ H: 2.7(3H, s), 3.9(3H, s), 6.7(1H, s), 6.8(1H, d, J=8.5 Hz), 7.0(1H, dd, J=2.1 & 8.4 Hz), 7.3(1H, d, J=2.4 Hz), 7.5(2H, d, J=8.5 Hz), 7.6(2H, d, J=8.5 Hz).						
43.	H	H	CF ₃		Mol. Wt. = 459	% Yield = 55
¹ H: 2.7(3H, s), 3.9(3H, s), 6.7(1H, s), 6.8(1H, d, J=8.5 Hz), 7.0(1H, dd, J=2.1 & 8.5 Hz), 7.4-7.5(3H, m), 7.6(2H, d, J=8.5 Hz).						
44.	H	H	CF ₃		Mol. Wt. = 398	% Yield = 73
¹ H: 2.7(3H, s), 3.9(3H, s), 6.7(1H, s), 6.9(3H, m), 7.4(2H, d, J=8.5 Hz), 7.6(2H, d, J=8.5 Hz).						
45.	H	H	CF ₃		Mol. Wt. = 394	% Yield = 71
¹ H: 2.2(3H, s), 2.7(3H, s), 3.6(3H, s), 6.6(1H, d, J=1.2 Hz), 6.6-6.7(1H, dd, J=1.4 & 7.6 Hz), 6.7(1H, s), 7.0-7.1(1H, d, J=7.6 Hz), 7.5(2H, d, J=8.6 Hz), 7.6(2H, d, J=8.6 Hz).						
46.	H	F	CF ₃		Mol. Wt. = 398	% Yield = 51
¹ H: 2.7(3H, s), 3.8(3H, s), 6.7(1H, s), 6.8(2H, d, J=8.8 Hz), 7.1(2H, d, J=8.8 Hz), 7.4(2H, m), 7.6(1H, m).						
47.	F	H	CF ₃		Mol. Wt. = 398	% Yield = 77
¹ H: 2.8(3H, s), 3.8(3H, s), 6.7(1H, s), 6.9(2H, d, J=8.8 Hz), 7.1(2H, d, J=8.8 Hz), 7.2(2H, m), 7.8(1H, t, J=7.8 Hz).						

48.	H	H	CF ₃		Mol. Wt. = 350	% Yield = 36
49.	H	H	CH ₃		Mol. Wt. = 326	% Yield = 80
50.	H	H	CF ₃		Mol. Wt. = 395	% Yield = 82
51.	H	H	CF ₃		Mol. Wt. = 380	% Yield = 68
52.	H	H	CF ₃		Mol. Wt. = 416	% Yield = 49
53.	H	H	CF ₃		Mol. Wt. = 396	% Yield = 83
54.	H	H	COOH		Mol. Wt. = 356	% Yield = 63
55.	H	H	CH ₂ OH		Mol. Wt. = 342	% Yield = 80
56.	H	H	CF ₃		Mol. Wt. = 410	% Yield = 70

57.	H	H	CF ₃		Mol. Wt. = 351	% Yield = 25.9
	¹ H: 2.89(3H, s), 7.66(1H, s), 7.84(2H, d, J=8.55 Hz), 7.9(4H, m), 8.6(2H, d, J=5.7 Hz).					
58.	H	H	CF ₃		Mol. Wt. = 351	% Yield = 61.3
	¹ H: 2.8(3H, s), 7.1(1H, s), 7.4(1H, m), 7.75(2H, d, J=8.58 Hz), 7.8(2H, d, J=8.64 Hz), 8.1(1H, m), 8.6(1H, dd, J=4.74 & 1.2 Hz), 9.0(1H, d, J=1.53 Hz).					
59.	H	H	CF ₃		Mol. Wt. = 351	% Yield = 27.8
	¹ H: 2.8(3H, s), 7.3(1H, dd, J=9.0 & 1.2 Hz), 7.54(1H, s), 7.8(5H, m), 8.0(1H, d, J=8.0 Hz), 8.67(1H, d, J=4.5 Hz).					
60.	H	H	CF ₃		Mol. Wt. = 356	% Yield = 54
	¹ H: 2.76(3H, s), 6.8(1H, s), 6.9(1H, dd, J=3.7 & 1.05 Hz), 7.0(1H, dd, J=5.0 & 3.6 Hz), 7.4(1H, dd, J=5.1 & 1.1 Hz), 7.6(2H, dd, J=8.5 & 1.9 Hz), 7.7(2H, dd, J=8.5 & 1.9 Hz).					

Preparation 3

5 5-(3-Fluoro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole (Compound No.74)




To a solution of 5-(3-fluoro-4-methoxyphenyl)-1-(4-methylsulfinylphenyl)-3-trifluoromethyl-1H-pyrazole (Compound No.44) (570 mg) in chloroform (25 mL) were added sodium azide (186 mg) followed by concentrated sulfuric acid (0.14 mL) at 0 °C and stirred at 40 °C for 18 h. An equal amount of sodium azide and sulfuric acid that were added earlier was added every two hours for four times and stirred for further four hours thereafter at 40 °C. The reaction mixture was cooled to 20 °C, diluted with chloroform (50 mL), washed with saturated aqueous solution of sodium bicarbonate (2 X

50 mL), water (50 mL), dried over calcium chloride and evaporated under reduced pressure to afford the product (500 mg) as a thick liquid.









In like manner compounds in the table 3 were prepared following the procedure described above

5










Table 3:




	X ₂	X ₁	R ₄	R ₃	Mol. Wt	Yield
61.	H	H	CF ₃		Mol. Wt. = 383	% Yield = 36
	¹ H, CD ₃ OD: 3.8(3H, s), 6.9(1H, s), 7.0(2H, t, J=8.7 Hz), 7.2(2H, m), 7.6(2H, d, J=8.9 Hz), 8.1(2H, d, J=8.9 Hz).					
62.	H	H	CF ₃		Mol. Wt. = 399.5	% Yield = 72
	¹ H, CD ₃ OD: 3.8(3H, s), 7.0(1H, s), 7.3(2H, d, J=8.7 Hz), 7.4(2H, d, J=8.6 Hz), 7.7(2H, d, J=8.9 Hz), 8.2(2H, d, J=9.0 Hz).					
63.	H	H	CF ₃		Mol. Wt. = 379	% Yield = 71
	¹ H: 2.3(3H, s), 3.1(3H, s), 6.7(1H, s), 7.1(2H, d, J=8.1 Hz), 7.18(2H, d, J=8.1 Hz), 7.5(2H, d, J=8.5 Hz), 7.9(2H, d, J=8.5 Hz).					
64.	H	H	CF ₃		Mol. Wt. = 395	% Yield = 51
	¹ H, CD ₃ OD: 3.8(3H, s), 3.9(3H, s), 6.9(1H, s), 6.9(2H, d, J=8.7 Hz), 7.2(2H, d, J=9.0 Hz), 7.7(2H, d, J=9.0 Hz), 8.2(2H, d, J=9.1 Hz).					
65.	H	H	CF ₃		Mol. Wt. = 423	% Yield = 33
	¹ H, dMSO-d ₆ : 1.0(3H, t, J=7.4 Hz), 1.8(2H, m), 3.8(3H, s), 3.9(2H, t, J=6.4 Hz), 6.9(2H, d, J=8.7 Hz), 6.9(1H, s), 7.2(2H, d, J=8.7 Hz), 7.7(2H, d, J=8.8 Hz), 8.19(2H, d, J=8.8 Hz).					

66.	H	H	CF ₃		Mol. Wt. = 409	% Yield = 22
¹ H, CD ₃ OD: 1.2(3H, t, J=6.9 Hz), 3.7(3H, s), 3.9(2H, q, J=6.9 Hz), 6.8(1H, s), 6.8(2H, d, J=8.8 Hz), 7.1(2H, d, J=8.8 Hz), 7.6(2H, d, J=8.9 Hz), 8.1(2H, d, J=8.9 Hz).						
67.	H	H	CF ₃		Mol. Wt. = 381	% Yield = 66
¹ H, CD ₃ OD: 3.8 (3H, s), 6.7(2H, d, J=8.6 Hz), 6.8(1H, s), 7.1(2H, d, J=8.6 Hz), 7.7(2H, d, J=8.9 Hz), 8.2(2H, d, J=8.9 Hz).						
68.	H	H	CF ₃		Mol. Wt. = 417.5	% Yield = 95
¹ H, CD ₃ OD: 3.89(3H, s), 7.0(1H, s), 7.3(2H, d, J=7.7 Hz), 7.5(1H, d, J=6.9 Hz), 7.8(2H, d, J=8.9 Hz), 8.2(2H, m).						
69.	H	H	CF ₃		Mol. Wt. = 401	% Yield = 96
¹ H, CD ₃ OD: 3.9(3H, s), 7.0(1H, s), 7.2(1H, m), 7.3(2H, m), 7.8(2H, d, J=8.8 Hz), 8.2(2H, d, J=8.8 Hz).						
70.	H	H	CF ₃		Mol. Wt. = 397	% Yield = 47
¹ H, CD ₃ OD: 2.2(3H, s), 3.7(3H, s), 6.9(1H, s), 7.1(2H, m), 7.3(1H, d, J=7.2 Hz), 7.7(2H, d, J=8.9 Hz), 8.2(2H, d, J=8.9 Hz).						
71.	H	H	CF ₃		Mol. Wt. = 409	% Yield = 41
¹ H, CD ₃ OD: 2.1(3H, s), 3.3(3H, s), 3.8(3H, s), 6.9(1H, d, J=8.5 Hz), 7.0(1H, dd, J=2.1 & 8.5 Hz), 7.1(1H, s), 7.2(1H, d, J=1.52 Hz), 7.6(2H, d, J=8.6 Hz), 8.0(2H, d, J=8.7 Hz).						
72.	H	H	CF ₃		Mol. Wt. = 429.5	% Yield = 34.5
¹ H, CD ₃ OD: 3.8(3H, s), 3.9(3H, s), 6.9(1H, s), 7.0-7.1(1H, d, J=8.6 Hz), 7.2(1H, dd, J=2.1 & 8.2 Hz), 7.3(1H, d, J=2.1 Hz), 7.7(2H, d, J=8.9 Hz), 8.2(2H, d, J=8.9 Hz).						
73.	H	H	CF ₃		Mol. Wt. = 474	% Yield = 56
¹ H, CD ₃ OD: 3.9(3H, s), 3.92(3H, s), 6.9(1H, s), 7.0(1H, d, J=8.5 Hz), 7.2-7.3(1H, dd, J=2.1 & 8.5 Hz), 7.5(1H, d, J=2.1 Hz), 7.8(2H, d, J=8.9 Hz), 8.2(2H, d, J=8.9 Hz).						

74.	H	H	CF ₃		Mol. Wt. = 413	% Yield = 74
¹ H, CD ₃ OD: 3.89(3H, s), 3.9(3H, s), 6.9(1H, s), 7.1(3H, m), 7.7(2H, d, J=8.8 Hz), 8.2(2H, d, J=8.5 Hz).						
75.	H	H	CF ₃		Mol. Wt. = 409	% Yield = 40
¹ H: 2.2(3H, s), 2.7(3H, s), 3.6(3H, s), 6.6(1H, d, J=1.2 Hz), 6.6-6.7(1H, dd, J=1.4 & 7.6 Hz), 6.7(1H, s), 7.0-7.1(1H, d, J=7.6 Hz), 7.5(2H, d, J=8.6 Hz), 7.6(2H, d, J=8.6 Hz).						
76.	H	F	CF ₃		Mol. Wt. = 413	% Yield = 94
¹ H: 3.1(3H, s), 3.8(3H, s), 6.7(1H, s), 6.8(2H, dd, J=2.0 & 8.8 Hz), 7.1(2H, dd, J=2.0 & 8.8 Hz), 7.7(2H, m), 7.9(1H, m).						
77.	F	H	CF ₃		Mol. Wt. = 413	% Yield = 25
¹ H: 3.2(3H, s), 3.8(3H, s), 6.7(1H, s), 6.9(2H, d, J=8.8 Hz), 7.1(3H, m), 7.3(1H, dd, J=1.9 & 10.4 Hz), 7.9(1H, t, J=8.4 Hz).						
78.	H	H	CF ₃		Mol. Wt. = 365	% Yield = 32
¹ H, CD ₃ OD: 3.8(3H, s), 7.0(1H, s), 7.3-7.4(5H, m), 7.7(2H, d, J=8.7 Hz), 8.1(2H, d, J=8.8 Hz).						
79.	H	H	CH ₃		Mol. Wt. = 341	% Yield = 93
¹ H, CD ₃ OD: 2.35(3H, s), 3.8(3H, s), 3.89(3H, s), 6.4(1H, s), 6.9(2H, d, J=8.8 Hz), 7.2(2H, d, J=8.8 Hz), 7.7(2H, d, J=8.9 Hz), 8.1(2H, d, J=8.9 Hz).						
80.	H	H	CF ₃		Mol. Wt. = 410	% Yield = 92
¹ H, CD ₃ OD: 3.9(3H, s), 7.2(1H, s), 7.6(2H, d, J=8.9 Hz), 7.8(2H, d, J=8.9 Hz), 8.2(4H, m),						
81.	H	H	CF ₃		Mol. Wt. = 395	% Yield = 84
¹ H, CD ₃ OD: 3.7(3H, s), 3.9(3H, s), 6.9(2H, m), 7.0(2H, m), 7.3(1H, t, J=7.9 Hz), 7.8(2H, d, J=8.9 Hz), 8.2(2H, d, J=8.9 Hz).						
82.	H	H	CF ₃		Mol. Wt. = 431	% Yield = 90
¹ H, CD ₃ OD: 3.9(3H, s), 4.0(3H, s), 7.02(1H, s), 7.06(2H, d, J=2.7 Hz), 7.8(2H, d, J=8.9 Hz), 8.2(2H, d, J=8.9 Hz).						


83.	H	H	CF ₃		Mol. Wt. = 411	% Yield = 46
84.	H	H	COOH		Mol. Wt. = 371	% Yield = 56
85.	H	H	CH ₂ OH		Mol. Wt. = 357	% Yield = 46
86.	H	H	CH ₂ OSO ₃ H		Mol. Wt. = 437	% Yield = 28
87.	H	H	CF ₃		Mol. Wt. = 425	% Yield = 25
88.	H	H	CF ₃		Mol. Wt. = 366	% Yield = 78.3
89.	H	H	CF ₃		Mol. Wt. = 366	% Yield = 86.5
90.	H	H	CF ₃		Mol. Wt. = 366	% Yield = 88.8
91.	H	H	CF ₃		Mol. Wt. = 423	% Yield = 82

92.	H	H	CF ₃		Mol. Wt. = 371	% Yield = 14
¹ H, CD ₃ OD: 3.8(3H, s), 7.1(3H, m), 7.6(1H, dd, J=4.8 & 1.4 Hz), 7.8(2H, d, J=8.7 Hz), 8.2(2H, d, J=8.7 Hz).						

Preparation 4

5-Chloro-3-(4-methylsulfanylphenyl)-[2,3']bipyridinyl (Compound No.93)

5




A mixture of 3-[2-(4-methylsulfanylphenyl)acetyl]pyridine (0.9 g), 2-chloromalondialdehyde (0.98 g) and ammonium acetate (1.85 g) was heated to 130 °C for 16 h. while distilling off the acetic acid formed. The reaction mixture was cooled, basified with aqueous sodium carbonate, extracted with dichloromethane (2 X 100 mL) and dried over anhydrous sodium sulfate. The combined organic layer was heated with activated charcoal, filtered, and evaporated under reduced pressure. The crude product was chromatographed over silicagel

15 using 10 % to 50 % ethyl acetate in petroleum ether as eluent yielding 280 mg of product as a dark yellow solid.



In like manner compounds in the table 4 were prepared following the procedure described above.

Table 4:



20

Compound No.	R ₃	Molecular Weight	% yield
--------------	----------------	------------------	---------

93.		Mol. Wt. = 312.5	% Yield = 24.21
94.		Mol. Wt. = 326.5	% Yield = 26.24


¹H: 2.48(3H, s), 7.06-7.08(2H, d, J=8.4 Hz), 7.15-7.18(2H, d, J=8.4 Hz), 7.20-7.25(1H, m), 7.67-7.69(1H, m), 7.73-7.74(1H, d, J=2.3 Hz), 8.50-8.52(1H, dd, J=3.2 & 4.8 Hz), 8.57(1H, d, J=1.64 Hz), 8.6(1H, d, J=2.35 Hz)

¹H: 2.48(3H, s), 2.53(3H, s), 7.05-7.09(3H, m), 7.19-7.16(2H, d, J=6.39 Hz), 7.59-7.55(1H, d, J=8.04 Hz), 7.71-7.70(1H, d, J=2.34 Hz), 8.45-8.44(1H, d, J=2.25 Hz), 8.64-8.63(1H, d, J=2.37 Hz)

The sulfides obtained as per the procedure described in preparation 4 were converted to the corresponding sulfoxides by a procedure similar to that described in preparation 2 above.



5

Table 5:



10

15

Compound No.	R ₃	Molecular Weight	% yield
95.		Mol. Wt. = 328.5	% Yield = 44.16
96.		Mol. Wt. = 342.5	% Yield = 47


¹H: 2.76(3H, s), 7.28-7.30(1H, d, J=4.95 Hz), 7.34-7.37(2H, d, J=8.3 Hz), 7.61-7.64(2H, d, J=8.3 Hz), 7.73-7.76(1H, d, H=8 Hz), 7.78-7.79(1H, d, J=2.34 Hz), 8.54(2H, s), 8.72-8.73(1H, d, J=2.3 Hz)

¹H: 2.54(3H, s), 2.2.76(3H, s), 7.06-7.08(1H, d, J=8 Hz), 7.34-7.37(2H, d, J=8.37 Hz), 7.54-7.57(1H, dd, J=2.3 & 8 Hz), 7.6-7.63(2H, d, J=6.4 Hz), 7.7(1H, d, J=2.34 Hz), 8.4(1H, d, J=2.3 Hz), 8.7(1H, d, J=2.3 Hz).

The sulfoxides obtained as per the procedure described in Preparation 5 were converted to the corresponding sulfoximines by a procedure similar to that described in preparation 3 above.


5

Table 6:




Compound No.	R ₃	Molecular Weight	% yield
97.		Mol. Wt. = 343.5	% Yield = 44
	¹ H: 2.75(3H, s), 7.22-7.24(1H, m), 7.33-7.36(2H, d, J=8.2 Hz), 7.60-7.63(2H, d, J=8.2 Hz), 7.67-7.7(1H, d, J=8 Hz), 7.77-7.78(1H, d, J=2.3 Hz), 8.52-8.54(2H, s), 8.72(1H, d, J=2.3 Hz)		
98.		Mol. Wt. = 357.5	% Yield = 79
	¹ H: 2.54(3H, s), 3.14(3H, s), 7.10-7.13(1H, d, J=8.04 Hz), 7.36-7.39(2H, d, J=8 Hz), 7.60-7.64(1H, dd, J=2.3 & 8.04 Hz), 7.7(1H, d, J=2.3 Hz), 7.96-7.98(2H, d, J=8.5 Hz), 8.3(1H, d, J=2 Hz), 8.7(1H, d, J=2.4 Hz)		








- 10 The sulfides of general formula given below were prepared according to the procedures well known in the art (for example as described in WO 0181332).



The sulfides of general formula given above were converted to the corresponding sulfoxides by a procedure similar to that described in preparation 2 above

15 Table 7:




Compound No.	X ₂	X ₁	R ₃	Mol. Wt	Yield
99.	F	H		Mol. Wt. = 385	% Yield = 41.1
	¹ H: 2.9(3H, s), 5.2(2H, s), 7.05(1H, dd, J=1.5 & 10 Hz), 7.2(1H, dd, J=2 & 8.3 Hz), 7.3(1H, d, J=1.5 & 8.1 Hz), 7.4(1H, d, J=8.3 Hz), 7.5(1H, d, J=8.4 Hz), 7.9(1H, t, J=7.6 Hz).				
100.	F	H		Mol. Wt. = 350.5	% Yield = 70
	¹ H: 2.9(3H, s), 5.2(2H, s), 7.05(1H, dd, J=1.5 & 10 Hz), 7.3-7.4(5H, m), 7.8(1H, t, J=7.5 Hz)				
101.	F	H		Mol. Wt. = 316	% Yield = 33.3
	¹ H: 2.85(3H, s), 5.2(2H, s), 7.05(1H, dd, J=1.5 & 10 Hz), 7.34-7.37(1H, dd, J=1.5 & 8.1 Hz), 7.38-7.8(5H, m), 7.83-7.89(1H, t, J=7.7 Hz).				
102.	F	H		Mol. Wt. = 352	% Yield = 57.4
	¹ H: 2.87(3H, s), 5.2(2H, s), 7.03-7.07(1H, dd, J=1.5 & 10 Hz), 7.16-7.3(3H, m), 7.34-7.37(1H, dd, J=1.5 & 8.1 Hz), 7.9(1H, t, J=7.6 Hz).				
103.	F	H		Mol. Wt. = 376	% Yield = 66
	¹ H: 2.85(3H, s), 3.80(3H, s), 3.9(3H, s), 5.15(2H, s), 6.86-6.89(1H, d, J=8.2 Hz), 6.96-7.0(2H, m), 7.09-7.14(1H, dd, J=1.5 & 10.3 Hz), 7.4(1H, dd, J=1.5 & 8.07 Hz), 7.86-7.91(1H, t, J=7.6 Hz).				
104.	F	H		Mol. Wt. = 346	% Yield = 71.5
	¹ H: 2.86(3H, s), 3.84(3H, s), 5.14(2H, s), 6.91-6.95(2H, dd, J=2 & 6.87 Hz), 7.08-7.12(1H, dd, J=1.4 & 10.3 Hz), 7.36-7.39(3H, m), 7.84-7.89(1H, t, J=7.6 Hz)				
105.	F	H		Mol. Wt. = 330	% Yield = 35.4

¹H: 2.39(3H, s), 2.85(3H, s), 5.15(2H, s), 7.07-7.1(1H, dd, J=1.5 & 10.35 Hz), 7.2-7.32(4H, m), 7.34-7.38(1H, dd, J=1.5 & 8.1 Hz), 7.84-7.89(1H, t, J=7.6 Hz)



The sulfoxides of table 7 were converted to the corresponding sulfoximines by a procedure similar to that described in preparation 3 above.

5

Table 8:




Compound No.	X ₂	X ₁	R ₃	Mol. Wt	% Yield
106.	F	H		Mol. Wt. = 400	% Yield = 77
	¹ H: 3.3(3H, s), 5.18(2H, s), 7.15-7.27(3H, m), 7.747-7.5(1H, d, J=8.3 Hz), 7.58(1H, d, J=2 Hz), 7.97-8.02(1H, t, J=7.6 Hz).				
107.	F	H		Mol. Wt. = 365.5	% Yield = 77
	¹ H: 3.3(3H, s), 5.17(2H, s), 7.15-7.19(1H, dd, J=1.56 & 10.32 Hz), 7.24(1H, d, J=1.6 Hz), 7.32-7.42(4H, m), 7.95-8.0(1H, t, J=7.8 Hz)				
108.	F	H		Mol. Wt. = 331	% Yield = 47
	¹ H, dMSO-d ₆ : 3.30(3H, s), 5.39(2H, s), 7.32-7.36(3H, m), 7.42-7.5(4H, m), 7.83-7.88(1H, t, J=7.9 Hz).				
109.	F	H		Mol. Wt. = 367	% Yield = 67
	¹ H: 3.3(3H, s), 5.17(2H, s), 7.15-7.34(5H, m), 7.97-8.02(1H, t, J=7.7 Hz).				
110.	F	H		Mol. Wt. = 391	% Yield = 30
	¹ H: 3.3(3H, s), 3.8(3H, s), 3.9(3H, s), 5.15(2H, s), 6.85-6.88(1H, d, J=8.3 Hz), 6.93-6.96(1H, d, J=2 & 8.3 Hz), 7.0(1H, d, J=1.5 Hz), 7.20-7.24(1H, dd, J=1.5 & 8.1 Hz), 7.29-7.32(1H, dd, J=1.5 & 8.1 Hz), 7.93-7.98(1H, t, J=7.8 Hz).				

111.	F	H		Mol. Wt. = 361	% Yield = 48
	¹ H: 3.3(3H, s), 3.85(3H, s), 5.14(2H, s), 6.92-6.95(2H, d, J=6.78 Hz), 7.18-7.22(1H, dd, J=1.5 & 10.56 Hz), 7.27-7.30(1H, dd, 1.59 & 8.25 Hz), 7.35-7.38(2H, d, J=6.8 Hz), 7.92-7.98(1H, t, J=7.8 Hz)				
112.	F	H		Mol. Wt. = 345	% Yield = 69
	¹ H: 2.39(3H, s), 3.28(3H, s), 5.15(2H, s), 7.17-7.13(6H, m), 7.91-7.97(1H, t, J=7.8 Hz).				

Preparation 5

3-(3-Fluorophenyl)-4(4-methylsulfonyl)-3H-thiazol-2-one. (Compound No.113)

5



Step1: Preparation of ethyl(3-fluorophenyl)thiocarbamate.

A solution of 3-fluoroaniline (4 g) and bis(ethoxythiocarbonyl)sulfide (7.56 g) in 50 mL EtOH was stirred at ambient temperature for 24 h. The solvent was evaporated and the residue was triturated with pentane yielding 4.0 g of product as a light cream solid.

Step2: Preparation of 3-(3-fluorophenyl)-4-hydroxy-4(4-methylsulfonylphenyl)-thiazolidin-2-one.

A mixture of ethyl(3-fluorophenyl)thiocarbamate (1 g) (prepared in step1) and 2-bromo-1-(4-methylsulfonylphenyl)ethanone (1.4 g) in 20 mL of THF was refluxed for 8 h. A slight insoluble material was filtered, the solvent was then evaporated and the residue was taken up in dichloromethane. The organic solution was dried over sodium sulfate, evaporated and the residue was crystallized from ether giving 0.8 g of product as a pale yellow solid.

Step 3: Preparation of 3-(3-fluorophenyl)-4(4-methylsulfonyl)-3H-thiazol-2-one.


To a solution of 3-(3-fluorophenyl)-4-hydroxy-4-(4-methylsulfonylphenyl)-thiazolidin-2-one (1 g) (prepared in step2) in ethanol (50 mL) was added 0.5 mL of concentrated HCl

and refluxed for 5 h. The reaction mixture was cooled to 25 °C. Precipitated solid was filtered, washed with ethanol and dried to yield 0.8 g of product as a pale yellow solid.

In like manner compounds in the table 9 were prepared following the procedure described above

5


Table 9:








Compound No.	R ₃	Molecular Weight	% yield
113.		Mol. Wt. = 317	% Yield = 84
	¹ H: 2.45(3H, s), 6.18(1H, s), 6.89-7.09(6H, complex), 7.28-7.31(2H, m).		
114.		Mol. Wt. = 368	% Yield = 84
	¹ H: 2.46(3H, s), 6.18(1H, s), 6.88-6.92(1H, dd, J=2.43 Hz & 8.5 Hz), 6.96-6.99(2H, d, J=8.4 Hz), 7.09-7.12(2H, d, J=7.5 Hz), 7.35(1H, d, J=2.4 Hz), 7.37-7.40(1H, d, J=8.6 Hz).		

- 10 The sulfides described above were converted to the corresponding sulfoxides by a procedure similar to that described in preparation 2.

Table 10:




Compound No.	X	R ₃	Mol. Wt	% Yield
115. *	O		Mol. Wt. = 368	% Yield = 64.5
		¹ H: 2.74(3H, s), 6.9-7.0(1H, d, J=8.6 & 2.5 Hz), 7.1(1H, s), 7.2(2H, d, J=8.5 Hz), 7.4(1H, d, J=2.5 Hz), 7.4(1H, d, J=8.6 Hz), 7.6(2H, d, J=8.5 Hz).		

116. *	O		Mol. Wt. = 378	% Yield = 73
117. *	O		Mol. Wt. = 299	% Yield = 28
118. *	O		Mol. Wt. = 317	% Yield = 53
119.	S		Mol. Wt. = 333	% Yield = 76
120.	S		Mol. Wt. = 384	% Yield = 88

* The corresponding sulfides were prepared according to procedures known in the art.

Preparation 6

4-(4-Methylsulfoximinylphenyl)-3-(3,4-dichlorophenyl)-3H-oxazol-2-one
(Compound No.121)



- 5 To a stirred solution of 4-(4-methylsulfinylphenyl)-3-(3,4-dichlorophenyl)-3H-oxazol-2-one (Compound no. 115) (1.1 g) in 20 ml of dichloromethane was added O-mesitylenesulfonyl hydroxylamine (1.12 g) at 25 °C and stirred for 12 h. The reaction mixture was basified to pH 11 with 2N NaOH solution, stirred for 30 min and extracted with dichloromethane (3 X 100 mL), The organic extract was dried over anhydrous sodium sulfate and evaporated under reduced pressure.

The crude product obtained was chromatographed using 20 to 60 % ethyl acetate in petroleum ether as eluent to give 670 mg pure product as a gum.

In like manner compounds in the table 11 were prepared following the procedure described above.









Table 11:

Compound No.	X	R ₃	Mol. Wt	Yield
121.	O		Mol. Wt. = 383	% Yield = 32
		¹ H, CD ₃ OD: 3.6(3H, s), 7.0-7.1(1H, d, J= 2.4 & 8.6 Hz), 7.4-7.5 (4H, m), 7.59(1H, s), 8.0(2H, d, J=8.7 Hz).		
122.	O		Mol. Wt. = 393	% Yield = 57.7
		¹ H: 3.1(3H, s), 7.0(2H, d, J=6.7 Hz), 7.09(1H, s), 7.2(2H, d, J=6.2 Hz), 7.5(2H, d, J=8.7 Hz), 7.9(2H, d, J=8.4 Hz).		

123.	O		Mol. Wt. = 314	% Yield = 47
¹ H, CDCl ₃ +DMSO-d ₆ : 3.2(3H, s), 7.2(2H, d, J=8.1 Hz), 7.3(2H, d, J=9.0 Hz), 7.4(3H, m), 7.8(2H, d, J=8.5 Hz), 8.1(1H, s).				
124.	O		Mol. Wt. = 332	% Yield = 53
¹ H: 3.08(3H, s), 7.1(3H, m), 7.2(2H, d, J=8.49 Hz), 7.3-7.4(2H, m), 7.9(2H, d, J=8.5 Hz).				
125.	S		Mol. Wt. = 348	% Yield = 60
¹ H, CD ₃ OD: 3.8(3H, s), 6.8(1H, s), 7.0(1H, d, J=8.0 Hz), 7.09-7.16(2H, m), 7.3-7.4(1H, dd, J=6.3 & 8.0 Hz), 7.6(2H, d, J=8.6 Hz), 8.0(2H, d, J=8.6 Hz).				
126.	S		Mol. Wt. = 399	% Yield = 61
¹ H, dMSO-d ₆ : 3.5(3H, s), 6.9(1H, s), 7.2(1H, dd, J=2.4 & 8.5 Hz), 7.5(2H, d, J=8.5 Hz), 7.6(1H, d, J=8.5 Hz), 7.7(1H, d, J=2.4 Hz), 7.9(2H, d, J=8.4 Hz).				

Preparation 7

- 5 3-(3,4-Dichlorophenyl)-4-[4-(N-chloroacetyl) methylsulfoximinyphenyl]-3H-oxazol-2-one (Compound No.128)




To a solution of 3-(3,4-dichlorophenyl)-4-[4-methylsulfoximinyphenyl]-3H-oxazol-2-one (Compound No.119) (100 mg) and triethyl amine (0.18 mL) in dry THF (5 mL) was added chloroacetyl chloride (59 mg) at 0 °C. The reaction mixture was allowed to warm upto 25 °C and stirred for 2 h. The reaction mixture was quenched with water and extracted with dichloromethane (3 X 10 mL). The organic extract was washed with water followed by brine solution, dried over calcium chloride and evaporated under reduced

pressure. The crude product was purified over silicagel using 50 % ethyl acetate in petroleum ether as eluent yielding 70 mg of product as a yellow solid.

In like manner following compounds in table 12 were prepared by a procedure similar to that described above.


5

Table 12:



Compound No.	R ₁	R ₃	Mol. Wt	Yield
127.			Mol. Wt. = 424	% Yield = 69
	¹ H: 2.1(3H, s), 3.3(3H, s), 6.9(1H, d, J= 2.4 & 8.5 Hz), 7.1(1H, s), 7.3(2H, d, J=8.5 Hz), 7.4(1H, d, J=2.5 Hz), 7.4(1H, d, J=8.5 Hz), 7.9(2H, d, J=8.5 Hz).			
128.			Mol. Wt. = 460	% Yield = 50
	¹ H: 3.3(3H, s), 4.1(2H, s), 6.9(1H, dd, J= 2.5 & 8.5 Hz), 7.1(1H, s), 7.3(2H, d, J=8.6 Hz), 7.4(1H, d, J=2.4 Hz), 7.4(1H, d, J=8.5 Hz), 7.9(2H, d, J=8.67 Hz).			
129.			Mol. Wt. = 461	% Yield = 66
	¹ H: 3.1(3H, s), 3.4(3H, s), 6.9(1H, dd, J= 2.5 & 8.6 Hz), 7.1(1H, s), 7.3(2H, d, J=8.5 Hz), 7.4(1H, d, J=2.5 Hz), 7.4(1H, d, J=8.5 Hz), 7.9(2H, d, J=8.5 Hz).			
130.			Mol. Wt. = 537	% Yield = 53
	¹ H: 2.4(3H, s), 3.4(3H, s), 6.9(1H, dd, J= 2.5 & 8.6 Hz), 7.1(1H, s), 7.2-7.3(4H, m), 7.4(1H, d, J=2.4 Hz), 7.4(1H, d, J=8.6 Hz), 7.8(2H, d, J=8.3 Hz), 7.9(2H, d, J=8.6 Hz).			

Preparation 8
3-(4-Methoxyphenyl)-4-(4-methylsulfanyl)-5-methyl-isoxazole
(Compound No.138)



5

Step1: Preparation of 3-(4-methoxyphenyl)-4-(4-methylsulfanyl)-5-methyl-4,5-dihydro-isoxazol-5-ol.

To a stirred solution of 1-(4-methoxyphenyl)-2-(4-methylsulfanylphenyl)ethanone oxime (4.5 g) in dry THF (30 mL), was added a solution of *n*-butyl lithium (1.3 M, 30.7 mL) in hexane at -70°C over a period of 30 minutes. The reaction mixture was warmed to 20°C over a period of 2 h. To this was added ethyl acetate (2.1 mL) and the reaction mixture was stirred the same temperature for 30 minutes. The reaction mixture was quenched with cold water (100 mL) and extracted with ethyl acetate (3 X 100 mL). The organic extract was washed with water (100 mL),
15 brine (100 mL), dried over sodium sulphate and evaporated under reduced pressure. The crude product was chromatographed over silicagel using 10 % ethyl acetate in petroleum ether as eluent, yielding 4.1 g of pure product as a pale yellow solid.


Step2: Preparation of 3-(4-methoxyphenyl)-4-(4-methylsulfanyl)-5-methyl-isoxazole.

A solution of 3-(4-methoxyphenyl)-4-(4-methylsulfanyl)-5-methyl-4,5-dihydro-isoxazol-5-ol (2.1 g) and PTSA (100 mg) in benzene (20 mL) was refluxed for 30 minutes. The reaction mixture was cooled to 25°C , diluted with 50 mL of benzene and washed with water (50 mL) followed by brine solution (50 mL). The organic extract was dried over sodium sulphate and evaporated under reduced pressure to yield 1.7 g of product as a thick liquid.

25

Preparation 9

5-Chloro-4(4-methyl sulfanylphenyl)-3-phenyl isoxazole (compound.No.136)



Step1: Preparation of 5-hydroxy-4(4-methylsulfanylphenyl)-3-phenyl isoxazole.


To a stirred solution of 1- phenyl-2-(4-methylsulfanylphenyl) ethanone oxime (2.0 g) in dry THF (20 mL), was added a solution of *n*-butyl lithium (0.98 M, 25 mL) in hexane at -70 °C over a period of 30 minutes. The reaction mixture was warmed to 20 °C over a period of 2 h. To this was added solid CO₂ (25 g) and the reaction mixture was stirred at the same temperature for 30 minutes. The reaction mixture was quenched with cold 1N HCl (20 mL) and extracted with ethyl acetate (3 X 50 mL). The organic extract was washed with water (100 mL); brine (100 mL), dried over sodium sulphate and evaporated under reduced pressure. The crude product was chromatographed over silicagel using 10 % ethyl acetate in petroleum ether as eluent, yielding 1.2 g of pure product as a thick liquid.

Step2: Preparation of 5-chloro-4(4-methylsulfanylphenyl)-3-phenyl isoxazole.









To a mixture of 5-hydroxy-4(4-methylsulfanylphenyl)-3-phenyl isoxazole (Compound prepared in step1) (0.6 g) and triethylamine (0.43 mL) was added POCl₃ (10 mL) under stirring and the reaction mixture was heated to 70 °C for 4 h. Solvents were evaporated and the crude product was chromatographed over silicagel using petroleum ether as eluent to yield 310 mg of product as a pale yellow solid.

In like manner compounds in the following table were prepared following the procedure described in preparation 8.

Table 13:




Compound No.	R ₃	R ₄	Mol. Wt	% Yield
131.			Mol. Wt. = 295	% Yield = 44
	¹ H: 1.3(3H, t, J=7.6 Hz), 2.7(3H, s), 2.8(2H, q, J=7.6 Hz), 7.2-7.6(9H, complex).			


132.		$-\text{CH}_2\text{OCH}_3$	Mol. Wt. = 311	% Yield = 60
	^1H : 2.5(3H, s), 3.4(3H, s), 4.5(2H, s), 7.1-7.2(4H, m), 7.3(3H, m), 7.4(2H, m).			
133.		$-\text{CH}_3$	Mol. Wt. = 299	% Yield = 35
	^1H : 2.4(3H, s), 2.7(3H, s), 7.0(2H, t, $J=8.7$ Hz), 7.3(4H, m), 7.6(2H, d, $J=8.4$ Hz).			
134.		$-\text{CH}_3$	Mol. Wt. = 315.5	% Yield = 85
	^1H : 2.4(3H, s), 2.7(3H, s), 7.2-7.3(6H, m), 7.6(2H, d, $J=8.2$ Hz).			
135.			Mol. Wt. = 295	% Yield = 23
	^1H : 1.2(3H, t, $J=7.5$ Hz), 2.6(2H, q, $J=7.5$ Hz), 2.8(3H, s), 7.3(3H, m), 7.4(4H, m), 7.7(2H, d, $J=8.4$ Hz).			
136.		$-\text{Cl}$	Mol. Wt. = 301.5	% Yield = 49
	^1H : 2.7(3H, s), 7.2-7.4(7H, complex), 7.6(2H, d, $J=8.3$ Hz)			
137.		$-\text{CH}_3$	Mol. Wt. = 281	% Yield = 94
	^1H : 2.45(3H, s), 2.5(3H, s), 7.1(2H, d, $J=8.44$ Hz), 7.2(2H, d, $J=8.44$ Hz), 7.3(3H, m), 7.4(2H, m)			
138.		$-\text{CH}_3$	Mol. Wt. = 311	% Yield = 85
	^1H : 2.4(3H, s), 2.5(3H, s), 3.8(3H, s), 6.8(2H, dd, $J=6.8$ & 2.0 Hz), 7.1(2H, dd, $J=6.5$ & 1.9 Hz), 7.2(2H, dd, $J=6.57$ & 1.9 Hz), 7.3(2H, dd, $J=6.8$ & 2.0 Hz)			

The sulfides of table 13 were converted to the corresponding sulfoxides by a procedure similar to that described in preparation 2:

Table 14:




Compound No.	R ₃	R ₄	Mol. Wt	Yield
139.		CH ₃	Mol. Wt. = 311	% Yield = 67
	¹ H: 1.3(3H, t, J=7.6 Hz), 2.7(3H, s), 2.8(2H, q, J=7.6 Hz), 7.2-7.6(9H, complex).			
140.		-CH ₂ OCH ₃	Mol. Wt. = 327	% Yield = 72
141.		-CH ₃	Mol. Wt. = 315	% Yield = 87
	¹ H: 2.4(3H, s), 2.7(3H, s), 7.0(2H, t, J=8.7 Hz), 7.3(4H, m), 7.6(2H, d, J=8.4 Hz).			
142.		-CH ₃	Mol. Wt. = 331.5	% Yield = 79
	¹ H: 2.4(3H, s), 2.7(3H, s), 7.2- 7.3(6H, m), 7.6(2H, d, J=8.2 Hz).			
143.	CH ₃		Mol. Wt. = 311	% Yield = 71
	¹ H: 1.2(3H, t, J=7.5 Hz), 2.6(2H, q, J=7.5 Hz), 2.8(3H, s), 7.3(3H, m), 7.4(4H, m), 7.7(2H, d, J=8.4 Hz).			
144.		-Cl	Mol. Wt. = 317.5	% Yield = 51
	¹ H: 2.7(3H, s), 7.2-7.4(7H, complex), 7.6(2H, d, J=8.3 Hz)			
145.		-CH ₃	Mol. Wt. = 297	% Yield = 72
	¹ H: 2.5(3H, s), 2.8(3H, s), 7.3-7.4(7H, m), 7.6(2H, d, J=8.5 Hz)			






146.		$-\text{CH}_3$	Mol. Wt. = 327	% Yield = 78
^1H : 2.5(3H, s), 2.8(3H, s), 3.8(3H, s), 6.8(2H, dd, $J=6.82$ & 2.02 Hz), 7.3(4H, m), 7.6(2H, d, $J=8.3$ Hz)				




The sulfoxides of table 14 were converted to the corresponding sulfoximines by a procedure similar to that described in preparation 3:

Table 15:




5

Compound No.	R ₃	R ₄	Mol. Wt	Yield
147.		$-\text{CH}_2\text{CH}_3$	Mol. Wt. = 326	% Yield = 71
^1H , dMSO- d_6 : 1.3(3H, t, $J=7.6$ Hz), 2.8(2H, q, $J=7.6$ Hz), 3.79(3H, s), 7.4(5H, m), 7.6(2H, d, $J=8.5$ Hz), 8.1(2H, d, $J=8.5$ Hz).				
148.		$-\text{CH}_2\text{OCH}_3$	Mol. Wt. = 342	% Yield = 26
^1H , dMSO- d_6 : 3.3(3H, s), 3.4(3H, s), 4.5(2H, s), 7.4(5H, m), 7.5(2H, d, $J=8.4$ Hz), 8.0(2H, d, $J=8.4$ Hz).				
149.		$-\text{CH}_3$	Mol. Wt. = 330	% Yield = 41
^1H : 2.4(3H, s), 2.7(3H, s), 7.0(2H, t, $J=8.7$ Hz), 7.3(4H, m), 7.6(2H, d, $J=8.4$ Hz).				
150.		$-\text{CH}_3$	Mol. Wt. = 346.5	% Yield = 86
^1H , dMSO- d_6 : 3.4(3H, s), 3.5(3H, s), 7.3(2H, d, $J=8.5$ Hz), 7.4(2H, d, $J=8.5$ Hz), 7.5(2H, d, $J=8.4$ Hz), 8.0(2H, d, $J=8.7$ Hz).				
151.	$-\text{CH}_2\text{CH}_3$		Mol. Wt. = 326	% Yield = 63
^1H , dMSO- d_6 : 1.1(3H, t, $J=7.5$ Hz), 2.6(2H, q, $J=7.5$ Hz), 3.6(3H, s), 7.4(5H, m), 7.7(2H, d, $J=8.4$ Hz), 8.1(2H, d, $J=8.4$ Hz).				

152.		—Cl	Mol. Wt. = 332.5	% Yield = 57
	¹ H, dMSO-d ₆ : 3.3(3H, s), 7.3-7.4(5H, m), 7.5(2H, d, J=8.4 Hz), 8.0(2H, d, J=8.4 Hz)			
153.		—CH ₃	Mol. Wt. = 312	% Yield = 87
	¹ H: 2.5(3H, s), 3.2(3H, s), 7.3-7.4(7H, m), 7.6(2H, dd, J=6.7 & 1.8 Hz)			
154.		—CH ₃	Mol. Wt. = 342	% Yield = 30.2
	¹ H: 2.5(3H, s), 3.1(3H, s), 3.8(3H, s), 6.8(2H, d, J=8.8 Hz), 7.3(4H, m), 8.0(2H, d, J=8.3 Hz)			

Preparation 10

- 5 5-(4-Methylsulfoximinylphenyl)-1-phenyl -3- trifluoromethyl- 1H- pyrazole
(Compound No.155)



Step1: Preparation of 5-(4-methylsulfonylphenyl)-1-phenyl -3- trifluoromethyl- 1H-
pyrazole.

- 10 A solution of 4,4,4-trifluoro-(4-methylsulfonylphenyl)-butane-1,3-dione (3.0 g) and phenyl hydrazine hydrochloride (1.18 g) in ethanol (20 mL) was refluxed for 7 h. The solvent was evaporated and the residue was chromatographed over silicagel using 20 % ethyl acetate in petroleum ether as eluent yielding 2.25 g (% yield = 83, Mol. Weight=334) of product as a gum.
- 15 ¹H: 2.4(3H, s), 6.7(1H, s), 7.12(2H, dd, J=6.3 & 2.3 Hz), 7.15(2H, dd, J=6.3 & 2.2 Hz), 7.3(5H, m).

Step 2: Preparation of 5-(4-methylsulfinylphenyl)-1-phenyl -3- trifluoromethyl- 1H-
pyrazole.

Title compound (1.3 g, % yield =60, Mol. weight =350) was prepared from 5-(4-methyl sulfanylphenyl)-1-phenyl -3- trifluoromethyl-1H- pyrazole (2.1 g) (prepared in step 1 above) by a procedure similar to that described in preparation 2.

¹H: 2.7(3H, s), 6.8(1H, s), 7.3(2H, dd, J=6.2 & 2.0 Hz), 7.4(5H, m), 7.6(2H, dd, J=8.2 & 1.6 Hz),


Step 3: Preparation of 5-(4-methylsulfoximinylphenyl)-1-phenyl -3- trifluoromethyl-1H-pyrazole (Compound. No.155)

Title compound (310 mg, % yield = 45, Mol. weight =365) was prepared from 5-(4-methyl sulfinylphenyl)-1-phenyl-3-trifluoromethyl- 1H- pyrazole (600 mg)(prepared in step 2 above) by a procedure similar to that described in preparation 3.

¹H, CD₃OD: 3.8(3H, s), 7.17(1H, s), 7.3(2H, m), 7.4(3H, m), 7.7(2H, dd, J=8.7 & 1.8 Hz), 8.1(2H, dd, J=8.7 & 1.8 Hz).

Preparation 11


Hydrochloride salt of 5-(3-fluoro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole (Compound No. 167)



To 5-(3-fluoro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole (Compound. No.74) (500 mg), methanolic HCl (10 mL, 15 %) was added and stirred at 25-30 °C for 0.5 h. The solvent was evaporated under reduced pressure and the residual oil was stirred with diisopropyl ether to afford the product (440 mg) as a off white solid.

Preparation 12

Bisulphate salt of 5-(3-methoxy-4-methylphenyl)-1-(4-methylsulfoximinyl- phenyl)-3-trifluoromethyl-1H-pyrazole (Compound No.168)



To 5-(3-methoxy-4-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole (Compound No.75) (120 mg), a chilled solution of acetone (10 mL) containing sulfuric acid (28 mg) was added and stirred at 0 °C for 30 minutes. The solvent was evaporated under a flow of nitrogen and the residue was stirred with diisopropyl ether to afford the product (75 mg) as an off white solid.

In like manner compounds in the table 16 were prepared following the procedure described for the preparation of 11 - 12.

Table 16:


Compound No.	Free-base No.	Salt prepared	Melting Point(°C)*
156.	61	HCl	182
157.	62	HCl	200
158.	63	HCl	171
159.	64	HCl	178
160.	66	HCl	163
161.	68	H ₂ SO ₄	135
162.	69	H ₂ SO ₄	195
163.	70	HCl	150
164.	71	HCl	170
165.	72	HCl	178
166.	73	HCl	170

167.	74	HCl	168
168.	75	H ₂ SO ₄	192
169.	77	HCl	68
170.	78	HCl	163
171.	79	H ₂ SO ₄	141
172.	80	H ₂ SO ₄	181
173.	81	H ₂ SO ₄	165
174.	82	H ₂ SO ₄	174
175.	83	H ₂ SO ₄	199
176.	84	H ₂ SO ₄	214
177.	85	H ₂ SO ₄	115
178.	92	HCl	168
179.	121	HCl	178
180.	123	HCl	184
181.	124	HCl	170
182.	125	HCl	120
183.	126	HCl	176
184.	147	HCl	166
185.	148	HCl	171
186.	149	HCl	169
187.	151	HCl	169
188.	152	HCl	158
189.	153	HCl	168
190.	155	HCl	153

* The melting points were uncorrected and may vary in the range of $\pm 4^{\circ}\text{C}$

We claim:

1. A compound of formula (I) their analogs, their derivatives, their tautomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions, wherein G represents substituted or unsubstituted, single or fused groups selected from aryl group, heteroaryl or heterocyclic groups containing one or more heteroatom selected from O, S, N; preferably, G represents the groups A, B, C, D, E & F as described below:



- 10 R_1 represents hydrogen, substituted or unsubstituted groups selected from alkyl, aralkyl, acyl, alkylsulfonyl, arylsulfonyl groups; R_2 represents alkyl, aralkyl, alkoxy or $-NHR$ where R represents hydrogen or lower alkyl groups which may be suitably substituted; X_1 , X_2 , X_3 , X_4 may be same or different and represent hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino, thio, hydroxy, or substituted or unsubstituted groups selected from alkyl which may be linear or branched, alkenyl, cycloalkyl, alkoxy, cycloalkoxy, cycloalkoxyalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, carboxyalkyl, haloalkyl, aminoalkyl, cyanoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkyl, acyl, acyloxy, acyloxyalkyl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aralkenyl, acylamino, alkylamino, dialkylamino, aralkylamino, alkoxyamino, hydroxylamino, alkoxycarbonyl, aralkoxycarbonyl groups; two adjacent groups may form a methylenedioxy or a ethylenedioxy group; when G represents heterocycle "D", then atleast one of the groups defined by X_1 , X_2 , X_3 , X_4 is not hydrogen; R_3 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted, single or fused groups selected from aryl, aralkenyl, heteroaryl or heterocyclic groups; R_4 and R_5 is selected from hydrogen atom, halogen atom, carboxy,

substituted or unsubstituted groups selected from linear or branched alkyl, alkoxy carbonyl, hydroxyalkyl, alkoxyalkyl, phenyl groups; Y represents O or S; W represents O or S;

- 5 2. A compound according to claim 1, wherein the substituents on R₃ and R₄ are selected from cyano, nitro, halo, carboxyl, hydrazino, azido, formyl, amino, thio, hydroxy, ONO₂, alkyl-ONO₂ or substituted or unsubstituted groups selected from alkyl which may be linear or branched, perhaloalkyl, alkoxy, hydrazinoalkyl, alkylhydrazido, acyl, acyloxy, oxo, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, 10 alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfoximinyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aryloxy carbonyl, alkoxy carbonyl, aralkoxy carbonyl, alkoxy carbonyl alkyl, amidino, carboxamidoalkyl, acylamino, cyanoamidino, cyanoalkyl, N-aminocarbonylalkyl, N-arylaminocarbonyl, carboxyalkylaminocarboxy, N-alkylamino, N,N-dialkylamino, N-aryl amino, N- 15 aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-aryl amino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-aryl aminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-aryl aminoalkyl, arylthio, aralkylthio, N-alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, N,N-dialkylaminosulfonyl, N-alkyl-N-arylaminosulfonyl, alkoxy carbonyl, aminocarbonyl, cycloalkyl, heterocyclic, 20 heterocyclicalkyl, heteroaryl, heteroaralkyl, heteroaralkoxy, sulfamyl groups; two adjacent groups may form a methylenedioxy or a ethylenedioxy group.

3. A compound as claimed in claim 1 where suitable substituents on X₁, X₂, X₃, X₄ are selected from cyano, nitro, halo, carboxyl, hydrazino, azido, formyl, amino, thio, 25 hydroxy or substituted or unsubstituted groups selected from alkyl which may be linear or branched, alkoxy, alkoxy carbonyl, acyl, acylamino, acyloxy, hydrazinoalkyl, alkylhydrazido, carboxyalkyl, haloalkyl, aminoalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, alkoxy carbonyl, amidino groups.

30

4. A compound according to claim 1, wherein the pharmaceutically acceptable salts are salts of tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic

acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid & nitric acid.

5. A pharmaceutical composition comprising compounds as claimed in Claim 1 or a pharmaceutically-acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, excipients or solvate.
6. A pharmaceutical composition according to claim 1, in the form of a tablet, capsule, powder, granule, syrup, solution or suspension.
7. A pharmaceutical composition which comprises, a compound according to claim 4, as an active ingredient and a pharmaceutically acceptable carrier, diluent, excipients or solvate.
8. A pharmaceutical composition which comprises, a compound according to claim 4, in the form of a tablet, capsule, powder, granule, syrup, solution or suspension.
9. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of compound of claim 1 or a pharmaceutically acceptable salt thereof.
10. The method as claimed in claim 9 wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.
11. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of compound of claim 4.
12. The method as claimed in claim 11 wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.
13. A compound according to claim 1 which is selected from
 - 5-(4-Fluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
 - 5-(4-Chlorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
 - 5-(4-Methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
 - 5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
 - 1-(4-methylsulfoximinylphenyl)-5-(4-*n*-propoxyphenyl)-3-trifluoromethyl-1H-pyrazole
 - 5-(4-Ethoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
 - 5-(4-Hydroxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
 - 5-(3-Chloro-4-fluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

5-(3,4-Difluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
5-(4-Fluoro-3-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

5-(4-Methoxy-3-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

5-(3-Chloro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

5-(3-Bromo-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

10 5-(3-Fluoro-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

5-(3-Methoxy-4-methylphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

15 1-(2-Fluoro-4-methylsulfoximinylphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole

1-(3-Fluoro-4-methylsulfoximinylphenyl)-5-(4-Methoxyphenyl)-3-trifluoromethyl-1H-pyrazole

1-(4-Methylsulfoximinylphenyl)-5-phenyl-3-trifluoromethyl-1H-pyrazole

1-(4-Methylsulfoximinylphenyl)-5-(1-naphthyl)-3-trifluoromethyl-1H-pyrazole

20 5-(4-Methoxyphenyl)-3-methyl-1-(4-methylsulfoximinylphenyl)-1H-pyrazole

1-(4-Methylsulfoximinylphenyl)-5-(4-nitrophenyl)-3-trifluoromethyl-1H-pyrazole

5-(3-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

5-(3,5-Difluoro-4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

25 5-(3-Hydroxy-4-methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazole-3-carboxylic acid

3-(Hydroxymethyl)-5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazole

30 5-(4-Methoxyphenyl)-1-(4-methylsulfoximinylphenyl)-1H-pyrazol-3-ylmethylhydrogen sulphate


5-{4-(2-Hydroxy-ethoxy)phenyl}-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole

1-(4-Methylsulfoximinylphenyl)-5-(4-pyridyl)-3-trifluoromethyl-1H-pyrazole

- 1-(4-Methylsulfoximinylphenyl)-5-(3-pyridyl)-3-trifluoromethyl-1H-pyrazole
1-(4-Methylsulfoximinylphenyl)-5-(2-pyridyl)-3-trifluoromethyl-1H-pyrazole
5-(4-Isopropoxyphenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
1-(4-Methylsulfoximinylphenyl)-5-(2-thiophenyl)-3-trifluoromethyl-1H-pyrazole
5 5-(4-Methylsulfoximinylphenyl)-1-phenyl-3-trifluoromethyl-1H-pyrazole.
1-(4-Methoxyphenyl)-5-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole
5-Ethyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole
5-Methoxymethyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole
3-(4-Fluorophenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole
10 3-(4-Chlorophenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole
3-Ethyl-4-(4-methylsulfoximinylphenyl)-5-phenyl-isoxazole
5-Chloro-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole
5-Methyl-4-(4-methylsulfoximinylphenyl)-3-phenyl-isoxazole
3-(4-Methoxyphenyl)-5-methyl-4-(4-methylsulfoximinylphenyl)-isoxazole
15 3-(3,4-Dichlorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one
3-(4-Chlorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one
3-Phenyl-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one
3-(3,4-Difluorophenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one
3-(3,4-Dimethoxyphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one
20 3-(4-Methoxyphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one
3-(4-Methylphenyl)-4-(3-fluoro-4-methylsulfoximinylphenyl)-5H-furan-2-one
5-Chloro-3-(4-methylsulfoximinylphenyl)-6'-methyl-[2,3']bipyridinyl
5-Chloro-3-(4-methylsulfoximinylphenyl)-[2,3']bipyridinyl
3-(3-Fluorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-thiazol-2-one
25 3-(3,4-Dichlorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one
3-(3,4-Dichlorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-thiazol-2-one
3-(2-Fluorophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one
3-(4-Bromophenyl)-4-(4-methylsulfoximinylphenyl)-3H-oxazol-2-one
4-(4-Methylsulfoximinylphenyl)-3-phenyl-3H-oxazol-2-one
30 3-(3,4-Dichlorophenyl)-4-[4-(N-chloroacetyl) methylsulfoximinyl-phenyl]-3H-oxazol-2-one
one
3-(3,4-Dichlorophenyl)-4-[4-(N-acetyl) methylsulfoximinyl-phenyl]-3H-oxazol-2-one

3-(3,4-Dichlorophenyl)-4-[4-(N-methylsulfonyl)methylsulfoximinyl-phenyl]-3H-oxazol-2-one

- 5 3-(3,4-Dichlorophenyl)-4-[4-{N-(4-methylphenyl)sulfonyl}-methylsulfoximinyl-phenyl]-3H-oxazol-2-one
14. A compound according to claim 13, wherein the pharmaceutically acceptable salts are salts of tartaric acid, mandelic acid, fumaric acid, malic acid, lactic acid, maleic acid, salicylic acid, citric acid, ascorbic acid, benzene sulfonic acid, p-toluene sulfonic acid, hydroxynaphthoic acid, methane sulfonic acid, acetic acid, benzoic acid, succinic acid, palmitic acid, hydrochloric acid, hydrobromic acid, sulfuric acid & nitric acid.
15. A pharmaceutical composition, which comprises a compound as defined in claims 13 & 14, and a pharmaceutically acceptable carrier, diluents or excipients or solvate.
- 15 16. A pharmaceutical composition as claimed in claim 15, in the form of a tablet, capsule, powder, granules, syrup, solution or suspension.
17. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of compound of claims 13-16 or a pharmaceutically acceptable salt thereof.
- 20 18. Use of compounds or pharmaceutically acceptable salts thereof of the present invention, as defined in any of the preceding claims for the treatment of inflammation or inflammation-mediated diseases.
19. A process for the preparation of compounds of formula (I),



(I)


25

Where G represents substituted or unsubstituted, single or fused groups selected from aryl group, heteroaryl or heterocyclic groups containing one or more heteroatom selected from O, S, N; R₁ represents hydrogen, substituted or unsubstituted groups selected from


alkyl, aralkyl, acyl, alkylsulfonyl, arylsulfonyl groups; R_2 represents alkyl, aralkyl, or -NHR or -OR where R represents hydrogen or lower alkyl groups which may be suitably substituted;

X_1, X_2, X_3, X_4 may be same or different and represent hydrogen, cyano, nitro, halo, carboxyl, formyl, hydrazino, azido, amino, thio, hydroxy, or substituted or unsubstituted groups selected from alkyl which may be linear or branched, alkenyl, oximealkyl, alkoxy, haloalkoxy, hydroxyalkyl, alkoxyalkyl, thioalkyl, carboxyalkyl, haloalkyl, aminoalkyl, cyanoalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkoxycarbonylalkyl, acyl, acyloxy, acyloxyalkyl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, aralkoxyalkyl, aralkenyl, acylamino, alkylamino, dialkylamino, aralkylamino, alkoxyamino, hydroxylamino, alkoxycarbonyl, aralkoxycarbonyl groups; two adjacent groups may form a methylenedioxy or a ethylenedioxy group; R_3 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted, single or fused groups selected from aryl, heteroaryl or heterocyclic groups; R_4 and R_5 is selected from hydrogen atom, halogen atom, carboxy, substituted or unsubstituted groups selected from linear or branched alkyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, phenyl groups; Y represents O or S; W represents O or S;

said process comprising oxidizing a compound of formula (P) to get a compound of formula (Q) which is iminated with suitable reagents to get compound of formula (I) which may further be converted to their pharmaceutically acceptable salts, if desired.




20. The process as claimed in claim 19, where the groups representing G are preferably selected from A, B, C, D, E & F as described below, and all other symbols are as defined earlier.




21. A process for preparing compound of general formula (P) as defined in claims 19 & 20, which comprises:

- i. reacting haloketone of formula II with compound III to obtain mercapto compound of formula (P),




where G represents




and all other symbols are as defined earlier.

- ii. converting the oxime of formula VII to mercapto compound of formula (P),




- 5 where G represents



and all other symbols are as defined earlier;

- 10 iii. reacting the hydrazine of formula XI with 1,3-diketone of formula XII to form the mercapto compound of formula (P),




- 15 where G represents




and all other symbols are as defined earlier.

- 20 iv. reacting compound of formula XVII with compound of formula XVIII to get mercapto compound of formula (P),




where G represents



and all other symbols are as defined earlier;


5

v. reacting compound of formula XXI with compound of formula XXII to get mercapto compound of formula (P),



10

where G represents



and all other symbols are as defined earlier.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IN 03/00133

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D231/12 C07D401/04 C07D307/46 C07D263/38 C07D277/34
 C07D261/08 A61K31/34 A61K31/415 A61K31/42 A61K31/425
 A61K31/44 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PUIG, CARLES ET AL: "Synthesis and Biological Evaluation of 3,4-Diaryloxazolones: A New Class of Orally Active Cyclooxygenase-2 Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY (2000), 43(2), 214-223, XP002251891 chart 1, p.214; Table 1, p.217</p> <p style="text-align: center;">-/--</p>	1-21



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"8" document member of the same patent family

Date of the actual completion of the international search

8 September 2003

Date of mailing of the international search report

22/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Schuemacher, A

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IN 03/00133

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PENNING, THOMAS D. ET AL: "Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib" JOURNAL OF MEDICINAL CHEMISTRY (1997), 40(9), 1347-1365, XP002114833 the whole document ----	1-21
A	SHIN, S. S. ET AL: "2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001), 11(2), 165-168, XP004314839 the whole document ----	1-21
A	FRIESEN, RICHARD W. ET AL: "2-Pyridinyl-3-[4-(methylsulfonyl) phenyl] pyridines: selective and orally active cyclooxygenase -2 inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (1998), 8(19), 2777-2782, XP004139619 compounds 1-3, p.2777 table 1 ----	1-21
Y	US 6 020 343 A (BELLEY, MICHEL ET AL) 1 February 2000 (2000-02-01) claims 1,37-42 ----	1-21
A	US 5 859 257 A (TALLEY, JOHN J.) 12 January 1999 (1999-01-12) column 95 -column 98; claim 1 ----	1-21
Y	WO 01 083475 A (J. URIACH & CIA S.A., SPAIN) 8 November 2001 (2001-11-08) claims 1,4,11-15 ----	1-21
Y,P	EP 1 251 126 A (PHARMACIA CORPORATION, USA) 23 October 2002 (2002-10-23) claims 1,5-7,113-117 -----	1-21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IN 03/00133**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 9-12, 17 and 18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claim 1 relates to an extremely large number of possible compounds. In fact, the claim contains so many options, particularly due to the use of the terms "their analogs, their derivatives" that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claim impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely the compounds of formula (I) according to claim 1, for which G is A, B, C, D, E and F and those compounds recited in the examples of the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IN 03/00133

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6020343	A	01-02-2000	
		US 6169188 B1	02-01-2001
		US 5981576 A	09-11-1999
		AT 229515 T	15-12-2002
		AU 703871 B2	01-04-1999
		AU 7123696 A	07-05-1997
		BG 63391 B1	31-12-2001
		BG 102425 A	30-06-1999
		BR 9611015 A	14-09-1999
		CA 2233178 A1	24-04-1997
		WO 9714691 A1	24-04-1997
		CN 1200119 A	25-11-1998
		CZ 9801101 A3	16-09-1998
		DE 69625374 D1	23-01-2003
		DK 863891 T3	17-03-2003
		EA 795 B1	24-04-2000
		EE 9800080 A	15-10-1998
		EP 0863891 A1	16-09-1998
		ES 2187675 T3	16-06-2003
		HR 960458 A1	30-04-1998
		HU 9802506 A2	28-05-1999
		IL 123699 A	10-03-2002
		JP 11500146 T	06-01-1999
		JP 3337476 B2	21-10-2002
		JP 2001199954 A	24-07-2001
		NO 981628 A	27-05-1998
		NZ 319090 A	28-01-2000
		NZ 332820 A	26-05-2000
		PL 326203 A1	31-08-1998
		PT 863891 T	31-03-2003
		SI 863891 T1	30-04-2003
		SK 45098 A3	02-12-1998
		TR 9800585 T2	21-07-1998
		TW 426679 B	21-03-2001
		ZA 9608609 A	14-04-1997
US 5859257	A	12-01-1999	
		US 5633272 A	27-05-1997
		AT 223390 T	15-09-2002
		AU 699593 B2	10-12-1998
		AU 4867196 A	04-09-1996
		BR 9607035 A	04-11-1997
		CA 2212836 A1	22-08-1996
		CN 1181075 A ,B	06-05-1998
		CZ 9702546 A3	14-01-1998
		DE 69623444 D1	10-10-2002
		DE 69623444 T2	05-06-2003
		DK 809636 T3	06-01-2003
		EP 1223167 A2	17-07-2002
		EP 0809636 A1	03-12-1997
		ES 2183935 T3	01-04-2003
		FI 973292 A	10-10-1997
		JP 3267300 B2	18-03-2002
		JP 11503722 T	30-03-1999
		JP 2002179656 A	26-06-2002
		LU 91024 A9	04-08-2003
		NO 973711 A	06-10-1997
		NZ 302586 A	30-08-1999
		PL 321814 A1	22-12-1997
		PT 809636 T	31-12-2002

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IN 03/00133

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5859257	A		RU 2200158 C2 WO 9625405 A1 US 5985902 A ZA 9601150 A	10-03-2003 22-08-1996 16-11-1999 12-02-1997
WO 01083475	A	08-11-2001	ES 2166710 A1 AU 4838201 A BR 0110328 A CA 2407418 A1 EP 1281709 A1 WO 0183475 A1 NO 20025101 A US 2003114456 A1	16-04-2002 12-11-2001 07-01-2003 08-11-2001 05-02-2003 08-11-2001 20-12-2002 19-06-2003
EP 1251126	A	23-10-2002	EP 1251126 A2 US 2003032657 A1 US 2003149078 A1	23-10-2002 13-02-2003 07-08-2003

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.